CLINICAL MICROBIOLOGY REVIEWS, Oct. 1998, p.

589603
0893-8512/98/$04.0010
Copyright 1998, American Society for Microbiology. All Rights Reserved.

Vol. 11, No. 4

Klebsiella spp. as Nosocomial Pathogens: Epidemiology, Taxonomy,

Typing Methods, and Pathogenicity Factors
R. PODSCHUN*

AND

U. ULLMANN

Department of Medical Microbiology and Virology,

University of Kiel, Kiel, Germany
INTRODUCTION .......................................................................................................................................................589
EPIDEMIOLOGY .......................................................................................................................................................589
TAXONOMY OF THE GENUS KLEBSIELLA ......................................................................................................591
DIFFERENTIATION OF KLEBSIELLA SPECIES. ..............................................................................................591
TYPING OF KLEBSIELLA ISOLATES...................................................................................................................592
Biotyping ..................................................................................................................................................................592
Serotyping ................................................................................................................................................................592
Phage Typing ...........................................................................................................................................................592
Bacteriocin Typing ..................................................................................................................................................592
Molecular Typing Methods ...................................................................................................................................592
PATHOGENICITY FACTORS OF KLEBSIELLA .................................................................................................592
Capsular Antigens ..................................................................................................................................................593
Pili (Fimbriae).........................................................................................................................................................594
Type 1 (common) pili .........................................................................................................................................594
Type 3 pili ............................................................................................................................................................595
Serum Resistance and Lipopolysaccharide .........................................................................................................595
Siderophores ............................................................................................................................................................596
VACCINATION EFFORTS .......................................................................................................................................597
Lipopolysaccharides................................................................................................................................................597
Capsular Polysaccharides ......................................................................................................................................597
CONCLUDING REMARKS ......................................................................................................................................597
REFERENCES ............................................................................................................................................................598
by Klebsiella. The urinary tract is the most common site of
infection. Klebsiella accounts for 6 to 17% of all nosocomial
urinary tract infections (UTI) and shows an even higher incidence in specific groups of patients at risk, e.g., patients with
neuropathic bladders or with diabetes mellitus (25, 133). As a
cause of nosocomial gram-negative bacteremia, Klebsiella is
second only to Escherichia coli (35, 70, 181, 258).
In pediatric wards, nosocomial Klebsiella infections are especially troublesomeparticularly in premature infants and
intensive care units. Klebsiella species are often the pathogens
involved in neonatal sepsis (Table 1), in both early-manifestation and late-manifestation infections (90).
Due to the extensive spread of antibiotic-resistant strains,
especially of extended-spectrum b-lactamase (ESBL)-producing strains, there has been renewed interest in Klebsiella infections.

INTRODUCTION
Klebsiella is well known to most clinicians as a cause of
community-acquired bacterial pneumonia, occurring particularly in chronic alcoholics (40) and showing characteristic radiographic abnormalities (81) due to a severe pyogenic infection which has a high fatality rate if untreated.
The vast majority of Klebsiella infections, however, are associated with hospitalization. As opportunistic pathogens, Klebsiella spp. primarily attack immunocompromised individuals
who are hospitalized and suffer from severe underlying diseases such as diabetes mellitus or chronic pulmonary obstruction. Nosocomial Klebsiella infections are caused mainly by
Klebsiella pneumoniae, the medically most important species of
the genus. To a much lesser degree, K. oxytoca has been isolated from human clinical specimens. It is estimated that Klebsiella spp. cause 8% of all nosocomial bacterial infections in the
United States and in Europe. No great geographical variations
in frequency have been noted. In the United States, Klebsiella
accounts for 3 to 7% of all nosocomial bacterial infections,
placing them among the eight most important infectious
pathogens in hospitals (104, 211), and data collected from the
United Kingdom (26) and from Germany (242) are remarkably
similar to those reported by the Centers for Disease Control
and Prevention.
Table 1 lists the most frequent nosocomial infections caused

EPIDEMIOLOGY
Klebsiella spp. are ubiquitous in nature. Klebsiellae probably
have two common habitats, one being the environment, where
they are found in surface water, sewage, and soil and on plants
(15, 33, 71, 140, 214), and the other being the mucosal surfaces
of mammals such as humans, horses, or swine, which they
colonize. In this respect, the genus Klebsiella is like Enterobacter and Citrobacter but unlike Shigella spp. or E. coli, which
are common in humans but not in the environment.
In humans, K. pneumoniae is present as a saprophyte in the
nasopharynx and in the intestinal tract. Carrier rates differ
considerably from study to study. The detection rate in stool
samples ranges from 5 to 38%, while rates in the nasopharynx

* Corresponding author. Mailing address: Department of Medical

Microbiology, Christian-Albrechts-Universitat, Brunswiker Str. 4, 24105
Kiel, Germany. Phone: 431 5973305. Fax: 431 5973296. E-mail:
[email protected].
589

590

PODSCHUN AND ULLMAN

CLIN. MICROBIOL. REV.

TABLE 1. Hospital-acquired bacterial infections

caused by Klebsiella spp.
% of infections caused
by Klebsiella

Ranka

References

UTI
Pneumonia
Septicemia

617
714
415

57
24
38

Wound infections
Nosocomial infections
in intensive care
unit patients
Neonatal septicemia

24
417

611
49

26, 46, 104, 242

26, 44, 104
34, 35, 4547, 64, 70, 135,
181, 242, 258
104, 142, 242
26, 104, 226, 242

320

28

24, 84, 168, 235, 240, 247

Infection

Ranking of Klebsiella compared to all other bacterial pathogens.

range from 1 to 6% (62, 206, 208, 236). Because gram-negative

bacteria do not find good growth conditions on the human skin
(207), Klebsiella spp. are rarely found there and are regarded
simply as transient members of the flora (126).
These carrier rates change drastically in the hospital environment, where colonization rates increase in direct proportion to the length of stay. Even hospital personnel have elevated rates of Klebsiella carriage (42, 43, 52). Reported carrier
rates in hospitalized patients are 77% in the stool, 19% in the
pharynx, and 42% on the hands of patients (52, 62, 112, 193,
206, 215, 225). The high rate of nosocomial Klebsiella colonization appears to be associated with the use of antibiotics rather
than with factors connected with delivery of care in the hospital
(193, 206). Previous antibiotic therapy is significantly associated with acquisition of Klebsiella by the patient. In one study,
2 weeks after admission to the hospital, a two- to fourfold increase in the colonization rates with Klebsiella was observed
(193); this increase occurred primarily in patients receiving
antibiotics, especially in persons receiving broad-spectrum or
multiple antibiotics. In the hospital setting, the local antibiotic
policy is a major determinant of the colonization pattern. The
significance of increased colonization was illustrated by the
observation that the attack rate of Klebsiella nosocomial infection in patients carrying hospital-acquired intestinal Klebsiella
was four times as high as for noncarriers (215). Furthermore,
widespread use of antimicrobial therapy has often been held
responsible for the occurrence of multiply resistant Klebsiella
strains in hospitals (215, 239). Because these undesired effects
may be reversed by strict control of antibiotic use, demands for
strategies to avoid the overuse of antibiotics in prophylaxis and
empirical therapy are increasingly being expressed.
Apart from medical equipment (contaminated due to faulty
hygienic procedures) and blood products (89, 116, 198), the
principal reservoirs for transmission of Klebsiella in the hospital setting are the gastrointestinal tract of patients and the
hands of hospital personnel (156). The ability of this organism
to spread rapidly (129) often leads to nosocomial outbreaks,
especially in neonatal units (98). Of the 145 epidemic nosocomial infections reported in the literature published in English
between 1983 and 1991, 13 were caused by Klebsiella (68).
According to the statistics of the Centers for Disease Control
and Prevention, Klebsiella spp. account for 8% of endemic
hospital infections and 3% of epidemic outbreaks (227).
Especially feared are epidemic hospital infections caused by
multiresistant strains. In the 1970s, these strains were chiefly
aminoglycoside-resistant Klebsiella strains (48, 60, 138, 160).
Since 1982, strains that produce ESBLs, which render them
resistant to extended-spectrum cephalosporins, have evolved
(22, 53, 63, 85, 96, 113, 144, 146, 200). The hallmark of these

strains, resistance to ceftazidime, is observed in both K. pneumoniae and K. oxytoca isolates (224). In Europe, the b-lactamases of ceftazidime-resistant Klebsiella strains are commonly of
the SHV-5 type, whereas TEM-10 and TEM-12 are more prevalent in the United States (22, 85, 108, 130, 144, 179, 213, 243,
245). The incidence of ESBL-producing Klebsiella isolates in
the United States has been reported to be 5% of the K. pneumoniae strains tested in the National Nosocomial Infection
Study system (108). In Europe, the frequency of such strains
seems to be even higher. A percentage of 14 to 16% ESBL
producers among clinical Klebsiella isolates has been reported
for France and England (221). In particular regions or hospitals, the incidence can reach 25 to 40% (38). However, the
percentage of ceftazidime-resistant strains may be much
higher, because the conventional disc diffusion criteria used in
the routine laboratory underestimate the incidence of these
isolates (109).
ESBLs are usually plasmid mediated. Since these plasmids
are easily transmitted among different members of the Enterobacteriaceae, accumulation of resistance genes results in strains
that contain multiresistant plasmids. For this reason, ESBLproducing isolates are resistant to a variety of classes of antibiotics. Moreover, the emergence of these multiply resistant
Klebsiella strains is unfortunately accompanied by a relatively
high stability of the plasmids encoding ESBLs. Even years after
discontinuation of ceftazidime and other extended-spectrum
cephalosporins, continued colonization of patients by ESBLproducing Klebsiella strains has been observed (101). Risk factors for acquisition of these strains seem to be the length of
stay in hospital and the performance of invasive procedures
(132).
Since ESBL production frequently is accompanied by multiresistance to antibiotics, therapeutic options become limited.
So far, however, ESBL-producing Klebsiella strains have been
susceptible to carbapenems such as imipenem or meropenem.
Both antibiotics are the drugs of choice in the treatment of
infections due to ESBL-producing organisms. In this respect, a
recent observation is very disturbing. For the first time, ESBLproducing K. pneumoniae strains which showed an additional
resistance to imipenem have been isolated (30). These strains
possessed a transmissible plasmid-mediated AmpC-type b-lactamase. This development should be monitored closely, since
the emergence of imipenem-resistant ESBL-producing Klebsiella strains will have a serious impact on remaining therapeutic options.
In the last several years, the question has arisen whether it is
necessary to determine if each isolated Klebsiella strain is an
ESBL producer. The answer depends on the epidemiologic
situation of a country or a hospital, but it should definitely be
positive if a high percentage of ceftazidime-resistant strains is
to be expected. To date, two diagnostic tests have been most
commonly used for the detection of such isolates. In the double-disc synergy test, a disc of clavulanic acid and a disc of an
extended-spectrum cephalosporin such as ceftazidime are
placed close together on an agar surface inoculated with the
test organism (111). Enhancement of the zone of inhibition
around the cephalosporin disc towards the clavulanate-containing disc indicates the presence of an ESBL-producing
strain. A commercially available product is the ESBL screening
E test strip (AB Biodisk, Solna, Sweden). This method is based
on the evaluation of the difference between the antimicrobial
activity of ceftazidime alone compared to that of ceftazidime
plus clavulanic acid (119).
It should be kept in mind that a number of measures have
been recommended to prevent the nosocomial spread of Klebsiella. Strict adherence to basic epidemiological standards for

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

VOL. 11, 1998

TABLE 2. Species classification of the genus Klebsiella
by different taxonomic systemsa
Classification by:
Cowan

Bascomb

rskov

K. aerogenes
K. edwardsii
subsp. edwardsii
subsp. atlantae
K. pneumoniae
K. ozaenae
K. rhinoscleromatis

K. aerogenes/oxytoca/
edwardsii
K. pneumoniae
sensu stricto
sensu lato
K. ozaenae
K. rhinoscleromatis
K. unnamed group
Enterobacter aerogenes

K. pneumoniae
subsp. pneumoniae
subsp. ozaenae
subsp. rhinoscleromatis
K. oxytoca
K. terrigena
K. planticola (syn.
K. trevisanii)
K. ornithinolytica

Data from references 18, 31, 54, 110, 174, and 228.

the management of urinary catheters, intravenous tracheostomies, and wounds, maintenance and care of equipment, and
good hand-washing practices all help to prevent the spread of
nosocomial Klebsiella infections. Detailed information on this
subject is given in an excellent review by Montgomerie (156).
Another measure to control Klebsiella infections is the regulation of antibiotic use in the hospital to prevent misuse and
overuse of antibiotics. Furthermore, nosocomial infection surveillance is necessary to collect data that are used in the prevention and control of nosocomial Klebsiella infection rates.
TAXONOMY OF THE GENUS KLEBSIELLA
The taxonomy of Klebsiella is characterized by a nomenclature reflecting its colorful taxonomic history. Originally, the
medical importance of the genus Klebsiella (family Enterobacteriaceae) led to its being subdivided into three species
corresponding to the diseases they caused: K. pneumoniae,
K. ozaenae, and K. rhinoscleromatis. As the taxonomy became
increasingly refined due to the development of new methods
such as numerical taxonomy, the species classification in this
genus was continually revised. In time, three main classifications emerged, those of Cowan, Bascomb, and rskov (Table
2).
In the early 1980s, Klebsiella isolates from the environment,
which had previously been classified as Klebsiella-like organisms (groups J, K, L, and M), were increasingly being classi-

591

fied into provisional taxa (87). These groups gave rise to four
new species: K. terrigena (107), K. ornithinolytica (210), K. planticola (14), and K. trevisanii (82). In 1986, the last two species
were combined into one species, K. planticola, because of their
extensive DNA sequence homology (86). While originally considered to be without clinical significance and restricted to
aquatic, botanical, and soil environments, K. terrigena and
K. planticola have recently been reported as occurring in human clinical specimens (158, 189, 190). According to these
findings, particularly K. planticola has been isolated from human infections with a surprisingly high frequency of 3.5 to
18.5% among clinical isolates of Klebsiella species. More than
half of these isolates were recovered from respiratory tract
secretions; wound and urine isolates were the next most common (189). However, since most of the isolates were obtained
from polymicrobial specimens, it is difficult to estimate the
significance of these strains as causative agents of disease.
Nevertheless, 6 of the 94 isolates were recovered from monomicrobial specimens and could be assigned to corresponding
infections. Thus, at present it seems possible that in addition to
K. pneumoniae and K. oxytoca, a third Klebsiella species exists
that is able to cause human infections.
The adoption of a consistent nomenclature has been further
complicated by the fact that Great Britain and the former Commonwealth countries adhere to the classification of Cowan while
the USA prefers rskovs classification. Consequently, the
same bacterium may be called K. pneumoniae in one country
and K. aerogenes in another. Most European countries follow
the American example and recognize the worldwide predominant classification of rskov.
DIFFERENTIATION OF KLEBSIELLA SPECIES
Klebsiella species are usually identified and differentiated
according to their biochemical reactions. The genus is defined
as containing gram-negative, nonmotile, usually encapsulated
rod-shaped bacteria of the family Enterobacteriaceae, which
produce lysine decarboxylase but not ornithine decarboxylase
and are generally positive in the Voges-Proskauer test (75).
Within the genus Klebsiella, the individual species can be differentiated on the basis of the features listed in Table 3. Whereas most Klebsiella species can be identified by standard microbiological laboratory tests, the species K. terrigena and

TABLE 3. Biochemical reactions of Klebsiella speciesa

Characteristic

Indole
Ornithine decarboxylase
Lysine decarboxylase
Pectate degradation
Gas from lactose at 44.5C
Growth at 10C
Acid from:
D-Melezitose
L-Sorbose
Utilization of:
m-Hydroxybenzoate
Hydroxy-L-proline
Malonate
Methyl red test
Voges-Proskauer reaction
a
b

Klebsiella pneumoniae

K. oxytoca

K. terrigena

K. planticola

K. ornithinolytica

2
2
2
2
2
2

1
2
1
1
2
1

2
2
1
2
2
1

vb
2
1
2
2
1

1
1
1
2
2
1

v
1

1
1

2
1

2
1
1
2

1
v
1
1
1

2
1
1
v
1

2
1
2

1
v
1
2
1

subsp. pneumoniae

subsp. ozaenae

subsp. rhinoscleromatis

2
2
1
2
1
2

2
2
v
2
2
2

2
v
2
v
1
2
1

Data summarized from references 14, 79, 107, 153, 154, 174, 210, and 228.
v, variable reaction.

1
1
1

592

PODSCHUN AND ULLMAN

K. planticola require special, nonconventional reactions (such

as utilization of m-hydroxybenzoate or hydroxy-L-proline, pectate degradation, acid from melezitose, or growth at 10C).

CLIN. MICROBIOL. REV.

priate efforts are made, as a number of reports have demonstrated (143, 180, 237).
Bacteriocin Typing

TYPING OF KLEBSIELLA ISOLATES

From an epidemiological point of view, it is often necessary
to determine the clonality of the strains. This is particularly
important in endemic and epidemic nosocomial outbreaks of
Klebsiella infections to improve the management of such outbreaks. A variety of methods have been used with various
degrees of success in Klebsiella typing and are discussed below.
Biotyping
Biotyping based on an extended panel of biochemical and
culture tests is certainly the most practicable method of typing
for smaller laboratories that are epidemiologically not optimally equipped. Biotyping can be carried out by using macrotube tests alone (100, 202) or by combining a commercially
available miniaturized system such as the API 20E system with
additional macrotube tests (185, 217). However, because of the
large number of reactions to be tested and the often long
cultivation timesup to 90 days for demonstration of gelatinase (228)biotyping of Klebsiella spp. is not very suitable as
an epidemiological tool.
Serotyping
Serotyping is currently the most widely used technique for
typing Klebsiella spp. It is based mainly on a division according
to the capsule antigens (177). Klebsiellae usually have welldeveloped polysaccharide capsules, which give their colonies
their characteristic mucoid appearance. Of 82 capsule antigens
described, 77 types form the basis for an internationally recognized capsule antigen scheme (176). Although 12 different
O-antigen types of Klebsiella have also been described, they are
difficult to classify because their determination is hampered by
the heat-stable capsules (175, 177). Capsule typing, by contrast,
shows good reproducibility and is capable of differentiating
most clinical isolates (12). The drawback of this method is the
large number of serological cross-reactions that occur among
the 77 capsule types. Thus, individual sera have to be absorbed
with the cross-reacting K-antigens. Moreover, the typing procedure is cumbersome because of the time needed to perform
the test and is susceptible to subjective interpretations because
of weak reactions that are not always easy to interpret. Since
anti-capsule antisera are not commercially available, this technique is practiced mostly in specialized laboratories. However,
in contrast to capsule typing, neither biochemical typing, bacteriocin typing, nor phage typing alone is sufficiently discriminative and reproducible for epidemiological purposes except
under certain conditions (177). The combined use of biotyping
and capsule typing enables the differentiation of a large number of bioserotypes (202).
Phage Typing
Phage typing of Klebsiella was first developed in the 1960s
(196, 223). Although the phage reaction is easily read and the
reproducibility of the method is acceptable, this technique
shows a relatively poor typing rate of 19 to 67% (209, 222).
Since it is not an alternative to capsule typing, this procedure
has never become widespread and is useful mainly as a secondary method in combination with serologic testing (48, 53,
113). It should be stressed, however, that it is possible to develop capsule- and O-antigen-specific phage typing if appro-

Although capsule typing is the preferred method for Klebsiella, it has been advised to include an additional feature
independent of the capsule type to enable more precise epidemiological analysis. Many authors recommend typing Klebsiella via bacteriocins (20, 36, 73, 97, 223). Bacteriocins are
bactericidal substances, usually proteins, produced by bacteria
to inhibit the growth of other bacteria, usually members of the
same species. An isolate can be characterized either by its
ability to inhibit specific indicator strains or by its sensitivity to
bacteriocins synthesized by a set of producer strains. Since the
synthesis of bacteriocins is not frequent enough in Klebsiella,
the latter technique has become the method of choice for
bacteriocin typing of organisms belonging to this genus. However, the two principal early methodsthe growth-in-broth
method and the cross-streak methodboth show considerable
disadvantages. Because of the instability of bacteriocin preparations, the reproducibility of the growth-in-broth method is
low. In addition, the conventional cross-streak method results
in low typability of strains (36, 73, 97). The limitations of both
of these methods have been surmounted by a modification of
the scrape-and-point procedure (20), which avoids the use of
potentially unstable preproduced and stored bacteriocins. Instead, the bacteriocins are synthesized on an agar medium
immediately before the strains to be typed are inoculated by a
multipoint inoculator. This method has proven superior for
bacteriocin typing of clinical and environmental Klebsiella
strains (21, 187, 188) as well as of nosocomial outbreaks of
Klebsiella (22).
Molecular Typing Methods
Molecular typing methods, as applied to the genus Klebsiella,
are still in their infancy. Preliminary descriptions have been
presented on plasmid profiles (22, 28, 53, 99, 157, 185, 250),
ribotypes (8, 27, 28), multilocus enzyme analyses (51, 161), and
applications of pulsed-field gel electrophoresis (8, 91, 192).
The procedures vary from laboratory to laboratory and lack
standardization, making it difficult to compare them.
PATHOGENICITY FACTORS OF KLEBSIELLA
The terms pathogenicity factor and virulence factor are
used synonymously by some authors (212), while others lay
emphasis on a clear-cut distinction between them. In this review, the term pathogenicity defines the ability of a bacterium to cause disease while virulence is the measurement or
degree of pathogenicity of any bacterial species.
Nosocomial Klebsiella infections most commonly involve the
urinary and respiratory tracts. Since these two body sites differ
considerably with respect to the host defense mechanisms, it
should be expected that the pattern of virulence factors found
in UTI-causing strains of Klebsiella will differ from that observed in strains isolated from pulmonary sources of patients
with pneumonia.
The search for the pathogenic mechanisms of Klebsiella infections has identified a number of bacterial factors that contribute to the pathogenesis of these bacteria. Both in vitro and
in vivo models have been established to investigate the interaction of bacterial cells and the host. The use of animal models
has been a critical element in the study of Klebsiella pathogenicity by providing vital information that cannot be obtained
from in vitro studies. In particular, animal models have been

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

VOL. 11, 1998

593

FIG. 1. Schematic representation of Klebsiella pathogenicity factors.

established to study Klebsiella virulence factors in UTIs; mice

and rats seem to be appropriate animal types. Lower UTIs
have been investigated in the diuresis mouse or rat model of
cystitis by intravesicular injection of organisms (77, 134). To
study Klebsiella-mediated upper UTI, a rat model of experimental retrograde pyelitis has been established (78). Frequently, both models include scanning electron microscopy of the
surface of the bladder or renal pelvis.
The current research into the pathogenicity of Klebsiella
focuses on the group of five factors shown in Fig. 1.
Capsular Antigens
As mentioned above, klebsiellae usually develop prominent
capsules composed of complex acidic polysaccharides. The capsular repeating subunits, consisting of four to six sugars and,
very often, uronic acids (as negatively charged components),
can be classified into 77 serological types (177). Capsules are
essential to the virulence of Klebsiella (56, 69, 76, 103). The
capsular material forms thick bundles of fibrillous structures
covering the bacterial surface in massive layers (Fig. 2) (7).
This protects the bacterium from phagocytosis by polymorphonuclear granulocytes, on the one hand (186, 191, 218, 219), and
prevents killing of the bacteria by bactericidal serum factors,
on the other (252). The molecular mechanism presumably
consists of inhibiting the activation or uptake of complement
components, especially C3b (254). Apart from their antiphagocytic function, Klebsiella capsule polysaccharides have been
reported to inhibit the differentiation and functional capacity
of macrophages in vitro (260, 261). Moreover, injection of
large doses of Klebsiella capsular polysaccharide (CPS) may
even produce immunological paralysis, as has been demonstrated in mice that showed a dose-dependent decrease in the
production of antibodies to the specific capsular antigen (19).
While Klebsiella CPS were generally considered to mediate virulence properties, this consideration has recently been
abandoned because of the great differences in virulence observed among different capsular types: strains expressing the
capsule antigens K1 and K2 were found to be especially virulent in a mouse peritonitis model, whereas isolates of other
serotypes showed little or no virulence (120, 151). In experi-

mentally induced skin lesions in mice, Klebsiella strains of serotypes K1, K2, K4, and K5 were more virulent than were
those expressing other capsule types (220). At present, strains
expressing capsule types K1 and K2 are considered especially
likely to be virulent, although only a few of the 77 different K
antigens have been systematically studied in this regard.
The degree of virulence conferred by a particular K antigen
might be connected to the mannose content of the CPS. Capsular types with low virulence, such as the K7 or K21a antigen
(166, 191), contain repetitive sequences of mannose-a-2/3-mannose or L-rhamnose-a-2/3-L-rhamnose. These sequences are
recognized by a surface lectin of macrophages, which mediates
opsonin-independent (i.e., complement- and antibody-independent) phagocytosis, known as lectinophagocytosis (9). Lectinophagocytosis has been defined as nonopsonic phagocytosis
that is based on recognition between surface lectins on one cell
and surface carbohydrates on the opposing cell (164). Lectinophagocytosis may be mediated either by bacterial surface lectins such as fimbriae or by phagocyte lectins that act as receptors. Macrophages with the mannose-a-2/3-mannose-specific
lectin or mannose receptor recognize, ingest, and subsequently
kill Klebsiella serotypes containing the CPS repeating sequences
Mana2/3Man or L-Rhaa2/3L-Rha. In contrast, strains that lack
these repeating sequences are not recognized by macrophages
and hence phagocytosis does not take place. This model is
consistent with the marked virulence of K2, which completely lacks mannose-a-2/3-mannose structures (117, 166).
Thus, Klebsiella strains bearing capsule types devoid of these
mannose or rhamnose sequences should be more closely associated with infectious diseases.
Previous attempts to establish a correlation between individual Klebsiella serotypes and the site of infection or clinical
symptoms have produced a profusion of contradictory results.
Each study reports different capsular types as predominant (41,
59, 185, 202, 203, 217, 241). Geographical differences in serotypes may have contributed to this confusion. Most reports do
agree, however, that the K2 serotype is among the most common capsule types isolated from patients with UTI, pneumonia, or bacteremia. It can be assumed, therefore, that K2 is the
predominant serotype of human clinical isolates worldwide
whereas K2 strains are very rarely encountered in the environ-

594

PODSCHUN AND ULLMAN

CLIN. MICROBIOL. REV.

FIG. 2. Transmission electron micrograph of K. pneumoniae cells surrounded by thick layers of fibrillous capsular material. Courtesy of I. Ofek, Tel Aviv University,
Israel. Reprinted from reference 163 with permission of the publisher.

ment (33, 74, 140, 182). Thus, the observed predominance of

the K2 serotype in Klebsiella infections is quite consistent with
the concept of lectinophagocytosis. Since the host innate immune mechanisms interact with structures commonly found on
microorganisms, particular Klebsiella serotypes, such as the K2
type, which do not bear such structures, become selected.
The significance of capsular mannose-a-2/3-mannose sequences to the clearance of Klebsiella in the host is further
illustrated by recent findings of Ofeks group (118). They observed that surfactant protein A (SP-A), the main protein
component of lung surfactant, enhances the phagocytosis by
alveolar macrophages of Klebsiella K21a strains (which bear a
mannose-a-2/3-mannose containing capsule) but not of K2
isolates. Since the reaction was inhibited by mannan, the authors suggested that bacterial binding is mediated by the macrophage mannose receptor.
Pili (Fimbriae)
As a critical first step in the infectious process, microorganisms must come as close as possible to host mucosal surfaces
and maintain this proximity by attaching to the host cell (adherence). The adhesive properties in the Enterobacteriaceae
are generally mediated by different types of pili. Pili (otherwise
known as fimbriae) are nonflagellar, filamentous projections
on the bacterial surface. These structures are up to 10 mm long
and have a diameter of 1 to 11 nm (163); they consist of
polymeric globular protein subunits (pilin) with a molecular
mass of 15 to 26 kDa (115).
Pili are demonstrated mainly on the basis of their ability to
agglutinate erythrocytes of different animal species. Depending on whether the reaction is inhibited by D-mannose, these
adhesins are designated as mannose-sensitive or mannose-re-

sistant hemagglutinins (MSHA and MRHA), respectively

(178). Of the different types of pili described in enterobacteria,
there are two predominant types in Klebsiella spp. (171, 184,
195).
Type 1 (common) pili. Type 1 pili are the best investigated of
the bacterial adhesins. They are MSHA which agglutinate
guinea pig erythrocytes. The adhesion protein in this pilus type
is located on the fimbrial shaft and is capable of binding to
mannose-containing trisaccharides of the host glycoproteins
(13, 83). The sugar structures presumably consist of short oligomannose chains bound via N-glycosidic linkages to the glycoproteins (216). The relevance of these pili to bacterial virulence is thought to arise mainly from binding of the bacteria to
mucus or to epithelial cells of the urogenital, respiratory, and
intestinal tracts (16, 162, 244). Their role in the pathogenesis of
UTI was clarified mostly in studies on E. coli but has also been
described for K. pneumoniae in animal models (77, 78, 134).
Although associated primarily with the pathogenesis of lower
UTI (106), type 1 pili may also be involved in the pathogenesis
of pyelonephritis (78, 141). In this setting, these structures
have been shown to bind effectively to proximal tubulus cells
(248). Type 1 fimbriae are also capable of binding to soluble,
mannosyl-containing glycoproteins in urine, such as the TammHorsfall protein (199), or in saliva (13). These findings provide
an explanation for the fact that type 1 pili mediate bacterial
colonization of the urinogenital and respiratory tracts (50).
Adherence of bacteria to cells of the respiratory tract (11)
leads to impairment of colonization resistance in the upper airways, with a subsequent proliferation of facultative pathogenic
bacteria. This impairment may result in the development of
pneumonia, especially in patients undergoing long-term mechanical ventilation (254).

VOL. 11, 1998

In the appraisal of the pathogenic role of type 1 pili, however, the phenomenon of phase variation has to be taken
into account. As mentioned above, this type of adhesin mediates bacterial colonization of the host mucosal surfaces via a
rather nonspecific binding. In pathogenic microorganisms, colonization of the mucous membrane is followed by invasion of
the underlying tissue, with all of the subsequent events of
infectious pathogenesis. Once in the host tissue, however, the
type 1 pili are no longer of use to the bacteria, since they
trigger an opsonin-independent leukocyte activity known as
lectinophagocytosis (167). The repulsion forces separating bacterium and leukocyte are weakened by the hydrophilic character of these pili (169), thus enabling the adhesins to bind to
specific mannose-containing receptors on the leukocyte surface (205). Adhesin-binding triggers stimulation of the leukocyte (137), which ultimately leads to phagocytosis and intracellular killing of the bacterium (131). The bacterium counters
this form of host defense by switching off the expression of type
1 pili in tissue (134). Thus, while type 1 pili are important for
host colonization, their contribution to subsequent steps of
pathogenesis is less clear.
Type 3 pili. Unlike other fimbriae, type 3 pili agglutinate
only erythrocytes that have been treated with tannin. Although
its name, mannose-resistant, Klebsiella-like hemagglutination
(MR/K-HA), implies that this fimbrial type is synthesized only
by Klebsiella, later studies demonstrated that type 3 pili occur
in many enteric genera (50). Moreover, type 3 pili apparently
are not identical in all genera of enterobacteria, since serological studies showed considerable antigenic diversity (170).
Originally described as the adhesion organelles of Klebsiella
inhabiting plant roots (128), these pili were later found to be
capable of binding to various human cells. Strains of K. pneumoniae expressing type 3 pili adhere to endothelial cells, epithelia of the respiratory tract, and uroepithelial cells (105, 232,
256). In the kidneys, these pili mediate bacterial adhesion to
tubular basement membranes, Bowmans capsules, and renal
vessels (231). Binding to tannic acid-treated erythrocytes is
inhibited by spermidine, a polyamine that is also secreted in
urine (88). Since spermidine is exposed on the cell surface of
damaged erythrocytes, it has been suggested that MR/K hemagglutination is mediated by spermidine (88). This might explain why type 3 pili bind to tannic acid- or heat-treated erythrocytes but not to untreated erythrocytes.
The role of this fimbrial type in the pathogenetic process is
largely unknown. So far, the only evidence of a correlation
between the type 3 MrkD hemagglutinin and disease has been
the observation of expression of type 3 pili in Providencia
stuartii in catheter-associated bacteriuria (152). This species is
not a common cause of UTI in short-term-catheterized or
noncatheterized persons but has a much higher prevalence in
the urine of patients with long-term indwelling catheters. In
the above-mentioned study, it was demonstrated that the
higher prevalence of P. stuartii in catheter-associated bacteriuria was due to its ability to adhere and persist to the catheter
in the catheterized urinary tract by expression of the MR/K
hemagglutinin. Unfortunately, so far, no experimental animal
model has been established investigate the role of these pili in
infection. The structure of the corresponding host receptors is
unknown.
Three new types of Klebsiella adhesins have been recently
reported. The R-plasmid-encoded CF29K adhesin of K. pneumoniae has been demonstrated to mediate adherence to the
human intestinal cell lines Intestine-407 and CaCo-2 (61). This
adhesin type seems to be identical to the CS31-A adhesive
protein of human diarrheal E. coli strains (66) and belongs to
the K88 adhesin family. The available data suggest that CF29K

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

595

probably is a product of the transfer of CS31A genetic determinants from E. coli to K. pneumoniae strains in the human
intestine. A particular adherence pattern characterized by aggregative adhesion to intestinal cell lines is mediated by another new Klebsiella adhesin that seems to be composed of
capsule-like extracellular material (80). While the two adhesins
mentioned above are nonfimbrial, a third putative colonization
factor of the human gut is a new fimbria that has been termed
KPF-28 (67). Interestingly, this fimbrial type has been found in
the majority of K. pneumoniae strains producing CAZ-5/SHV4 type ESBL.
To date, however, little is known about the frequency and
distribution of these newly described adhesins, their geographical variations, their expression by different species of Klebsiella, their site of isolation from the host, or their significance
in pathogenicity.
Serum Resistance and Lipopolysaccharide
The first line of defense by the host against invading microorganisms includes, in addition to phagocytosis by polymorphonuclear granulocytes, the bactericidal effect of serum. The
serum bactericidal activity is mediated primarily by complement proteins. After their cascade-like activation, these proteins accumulate as membrane attack complex on the surface
of the microorganism (233). This complex consists of the terminal complement proteins C5bC9, which produce a transmembranous pore in the outer membrane of gram-negative
bacteria (197), leading to an influx of Na1 and subsequent
osmotic lysis of the bacteria (234). The complement cascade
can be activated by two different mechanisms: the classic complement pathway, which typically requires specific antibodies
to be activated, and the alternative complement pathway,
which can be activated even in the absence of antibodies. The
alternative pathway is also regarded as an early defense system
of innate immunity, which enables the host to react to invading
microorganisms even before specific antibodies are formed
(114). Both complement pathways lead, via the activation of
C3, to the formation of the opsonin C3b, which ultimately
results in formation of the terminal C5bC9 complex and thus
plays a key role in this defense system.
In response to this host defense, pathogenic microorganisms
have developed strategies to counter the serum bactericidal
effect. Most commensal gram-negative bacteria are sensitive to
the bactericidal effect of human serum, whereas pathogenic
strains often exhibit serum resistance properties (172). Thus,
clinical isolates of enterobacteria often show resistance to serum (249), and the feature serum resistance has been correlated with the onset of infection (172, 204) and severity of
symptoms (29, 92). Since the main role of the serum bactericidal system is thought to prevent microorganisms from invading and persisting in the blood, even differences in the degree
of bacterial serum susceptibility may determine whether a
strain is able to infect as well as the length of time it takes the
organisms to establish the infection.
To date, the exact mechanism underlying bacterial serum
resistance is unknown. Aside from various proteins of the
outer membrane, such as the TraT lipoprotein or porins (3,
155), primarily CPS and O antigens (lipopolysaccharides
[LPS]) have been implicated (49, 173, 194, 230, 237, 246, 252).
For Klebsiella, two hypotheses have been propounded (145).
First, capsule polysaccharides may cover and mask the underlying LPS and exhibit a surface structure that does not activate
complement. On the other hand, the O side chains of the LPS
may reach through the capsule layer and be exposed to the

596

PODSCHUN AND ULLMAN

exterior milieu in certain Klebsiella capsule types (238). Since

LPS is generally able to activate complement, C3b is subsequently deposited onto the LPS molecules. However, since
it is fixed preferentially to the longest O-polysaccharide side
chains, C3b is far away from the bacterial cell membrane.
Thus, the formation of the lytic membrane attack complex
(C5bC9) is prevented, and subsequent membrane damage
and cell death do not take place.
In addition to this steric hindrance of the lytic complement
action by LPS, the quantity of deposited C3b also determines
the degree of serum resistance (2). While serum-sensitive
strains activate both the classical and the alternative complement pathways, the smooth LPS of serum-resistant strains activates only the alternative pathway. The activation of both
complement pathways by serum-sensitive strains leads to higher levels of deposited C3b, resulting in greater damage and
bacterial killing.
It should be borne in mind, however, that all previous studies in this field were done with strains expressing the O1 serotype. Even though O1 is the most common O antigen found
among clinical Klebsiella isolates, a number of different O serotypes, many of them neutral polysaccharides, are known.
Originally there were 12 chemically different O types, but the
results of structural investigations later reduced the number of
Klebsiella O antigens to 8 (151). To date, it is unclear whether
serum resistance is mediated solely by the O1 antigen or whether this feature is generally conferred by Klebsiella LPS.
Nevertheless, even within a given O serotype, serum resistance does not seem to be a stable characteristic; environmental factors affect the composition and effect of LPS. Recently,
the influence of different osmolarity conditions on LPS was
demonstrated in Aeromonas hydrophila serotype O:34 (1); cells
grown at high osmolarity showed smooth LPS, whereas growth
at low osmolarity resulted in rough LPS. Correspondingly, cells
cultivated at high osmolarity were resistant to normal human
serum while bacteria grown at low osmolarity proved to be
serum sensitive. Thus, the same bacterial strain may be serum
resistant at host body sites with a high-osmolarity milieu, such
as the urinary tract, and serum sensitive at low-osmolarity body
locations like the respiratory tract.
Siderophores
The growth of bacteria in host tissue is limited not only by
the host defense mechanisms but also by its supply of available
iron. Iron is an essential factor in bacterial growth, functioning
mainly as a redox catalyst in proteins participating in oxygen
and electron transport processes (93). The supply of free iron
available to bacteria in the host milieu is extremely low, since
this element is bound intracellularly to proteins such as hemoglobin, ferritin, hemosiderin, and myoglobin and extracellularly to high-affinity iron-binding proteins such as lactoferrin
and transferrin. The level of free, bioavailable iron (10218 M)
is several thousandfold too low for normal bacterial growth
(37). The marked effect of the iron supply in the host body on
the pathogenesis of infections has been demonstrated for Klebsiella. After parenteral administration of iron in a guinea pig
model, the susceptibility to K. pneumoniae infections increased
dramatically (121).
Many bacteria attempt to secure their supply of iron in the
host by secreting high-affinity, low-molecular-weight iron chelators, called siderophores, that are capable of competitively
taking up iron bound to host proteins (94). Under iron-deficient conditions, e.g., in the host milieu, enterobacteria synthesize a variety of siderophores, which belong to two different
chemical groups, one consisting of the phenolate-type sidero-

CLIN. MICROBIOL. REV.

phores and one consisting of the hydroxamate-type siderophores.

The more common group consists of the phenolate-type
siderophores. Their best-known representative, enterobactin
(also known as enterochelin), is a cyclic trimer of 2,3-dihydroxy-benzoyl-serine. This siderophore appears to comprise
the main iron uptake system of enterobacteria and is synthesized by almost all clinical isolates of E. coli and Salmonella
spp. (93). Studies on the contribution of enterobactin to virulence have produced conflicting results. For example, Yancey
et al. (257) reported that Salmonella typhimurium mutants unable to produce this siderophore were less virulent in mice,
while Benjamin et al. (23) found no association between virulence and the ability to synthesize enterobactin. To date, the
role of enterobactin in virulence remains uncertain.
Among the hydroxamate-type siderophores, the ferrichromes (which are synthesized only by fungi), the ferrioxamines, and aerobactin are the most important. In contrast to
enterobactin, the contribution of aerobactin to bacterial virulence has been clearly demonstrated (65). While the thermodynamic stability constant of ferric enterobactin indicates a
much higher affinity for Fe(III) than that of ferric aerobactin
(Ks 1052 and 1023, respectively), aerobactin still seems to be far
more effective than enterobactin because of a number of physical advantages such as greater stability and better solubility
(255). Moreover, while enterobactin becomes hydrolyzed by an
esterase after delivery of iron, aerobactin can be recycled after
each turn of iron transport.
The observations of Martinez et al. (139) indicate that enterobacterial genera can be divided into two groups according
to their incidence of aerobactin synthesis. The group with a low
rate of aerobactin-producing strains (,20%) comprises genera
such as Serratia, Proteus, and Salmonella. The second group,
which includes the genus Escherichia, shows a high incidence of
aerobactin synthesis (.40%).
In the genus Klebsiella, the production of both enterobactin
and aerobactin has been demonstrated. However, while enterobactin is synthesized by almost all strains (183, 201, 251), aerobactin-positive Klebsiella isolates, irrespective of the species
or source of isolation, have been observed rarely (139, 183,
253). Enterobactin-positive Klebsiella isolates in animal models
were no more virulent than enterobactin-negative strains (147).
In contrast, an association between aerobactin synthesis and
the virulence of Klebsiella strains was unequivocally demonstrated by Nassif and Sansonetti (159). In this study, the aerobactin gene was cloned from the plasmids of some K. pneumoniae strains of serotypes K1 and K2 and transferred to a
nonvirulent (siderophore-negative) strain. The transformant then
exhibited markedly enhanced virulence in a mouse peritonitis
model.
Because of the common ability of strains to produce enterobactin, it has been speculated for a long time what additional advantage a bacterium, which already synthesizes enterobactin, might derive from aerobactin. The great advantage
of enterobactin over aerobactin is its high iron affinity, the
highest ever recorded for a ferric iron chelator. At pH 7.4, the
formation constant for ferric enterobactin is 1052, which is
magnitudes higher than that of transferrin (93). In contrast to
enterobactin, aerobactin is not an effective competitor for
transferrin-bound iron because of its much lower affinity for
ferric iron. Indeed, investigations have demonstrated that enterobactin sequesters iron predominantly from transferrin,
while the iron source of aerobactin is host cells (32). Thus,
production of these two siderophores may give access to both
sources of iron, resulting in enhanced growth in the host.
Data on the incidence of aerobactin-producing Klebsiella

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

VOL. 11, 1998

~ndicates that this siderophore does not play a central role in

the pathogenicity of the genus Klebsiella. It should be pointed
out, however, that clinical K. pneumoniae isolates, which do not
synthesize aerobactin themselves, are entirely capable of using
exogenously introduced aerobactin as their sole source of iron
(253). By synthesizing only the intrinsically expressed aerobactin receptor, such strains could derive an advantage over other
aerobactin-synthesizing bacteria in mixed infections. The aerobactin-mediated iron uptake system would thus be an indirect
contributor to the pathogenicity of the genus Klebsiella.
As in many enterobacteria, and as has been especially well
studied in E. coli, other factors have also been demonstrated in
Klebsiella spp. Although the production of cytotoxins (102, 127,
149, 150, 229), enterotoxins (95, 122125, 148) and hemolysin
(46, 17) has been sporadically described, these features probably play a rather minor role in Klebsiella.
VACCINATION EFFORTS
As stated above, most Klebsiella infections are acquired during hospital stays and account for 5 to 7.5% of all nosocomial
infections. The morbidity and mortality of severe systemic infections, such as bacteremia and pneumonia, remain high despite the use of appropriate antibiotic therapy. Fatality rates of
20 to 50% in Klebsiella bacteremia and of more than 50% in
Klebsiella pneumonia have been reported (35, 55, 64). Moreover, Klebsiella infections in pediatric wards have become a
major concern. In neonatal intensive care units, Klebsiella is
one of the three or four most common pathogens (98). This is
apparently related to the observation that premature neonates,
especially those in neonatal intensive care units are more likely
than other neonates to develop an intestinal flora in which
Klebsiella spp. are highly prevalent. These findings, taken together with the emergence of ESBL-producing multiresistant
strains, indicate the need for a means of immunological control
of Klebsiella infections. Such measures may include immunoprophylaxis (active vaccination of patients who are at risk) as
well as immunotherapy (passive immunization by hyperimmune sera).
Among the different cell constituents, two surface components are mainly being discussed as candidates for an antiKlebsiella vaccine: LPS and CPS.
Lipopolysaccharides
Due to their endotoxic properties, LPS are considered important in the pathology of septicemia. Until recently, Klebsiella LPS O antigens were generally considered to be masked
by the capsule polysaccharides and thus not to be exposed on
surface, leaving them inappropriate as vaccine candidates. Recent studies, however, demonstrated surface exposure of Oantigens in strains expressing particular capsular serotypes
(238). The small number of different Klebsiella O-types is a
great advantage with respect to their applicability as vaccines.
In contrast to the K antigens, only eight O types are known, O1
being the most commonly found O type in clinical isolates. A
multivalent LPS vaccine composed of these eight O antigens or
at least the inclusion of the common O1 antigen in a broad
spectrum capsular polysaccharide vaccine might be a promising approach. Recently, the administration of monoclonal antibodies to the Klebsiella O1 antigen has been reported to be
protective in a mouse model of lethal endotoxemia (136).
Moreover, the inclusion of O antigens in a multivalent Klebsiella vaccine formulation might be of additional benefit due to
strong adjuvant action, as has been demonstrated for the Klebsiella O3 lipopolysaccharide (259). A great drawback of active

597

immunization with LPS-containing vaccines, however, is adverse toxic reactions, which must be expected because of the
endotoxin content. Thus, each Klebsiella vaccine composed of
O antigens has to be rendered safe by sufficient detoxification
of the LPS.
Capsular Polysaccharides
CPS have been the obvious vaccine candidates for several
reasons. Capsules are produced by almost all Klebsiella strains;
they represent the outermost layer of surface structures in
contact with the host milieu, and they have been proven to be
highly immunogenic and nontoxic (57). A serious disadvantage
of a Klebsiella CPS vaccine is the great number of K antigens
(77 different antigens). However, in a study of the incidence of
the capsule types among bacteremic Klebsiella isolates, Cryz et
al. observed that only 25 serotypes made up 70% of all bacteremic strains (59). Based on their seroepidemiological findings,
they formulated a 24-valent Klebsiella CPS vaccine that subsequently was proven to be safe and immunogenic (58). To date,
this vaccine seems to be the most promising approach for
preventing sepsis caused by Klebsiella and has already passed
phase I human trials (72). The most recent study of the 24valent Klebsiella CPS vaccine demonstrated an excellent antibody response after active immunization in patients with acute
blunt or penetrating trauma (39).
CONCLUDING REMARKS
Klebsiellae are opportunistic pathogens and can give rise to
severe diseases such as septicemia, pneumonia, UTI, and soft
tissue infection. Typically, Klebsiella infections are nosocomial.
The hospitalized, immunocompromised patient with underlying diseases is the main target of these bacteria. Thus, Klebsiella infections may serve as a paradigm of hospital-acquired
infections. Their incidence of 5 to 7% of all hospital-acquired
infections ranks them among the most important nosocomial
pathogens.
In this context, some new trends have been observed in the
past several years.
(i) An increasing number of endemic and epidemic outbreaks in pediatric wards has been reported. Especially common are Klebsiella infections causing septicemia and meningitis
in newborns in neonatal intensive care units. Since more and
more of these outbreaks have been caused by multidrug-resistant strains, Klebsiella neonatal infections are becoming a major concern of the pediatrician. Especially peculiar has been
the repeated frequent isolation of multidrug-resistant Klebsiella isolates expressing serotype K55. It remains to be seen
whether this observation reflects the spread of a particular
neonatal Klebsiella clone.
(ii) Hospital outbreaks of multidrug-resistant Klebsiella spp.
are often caused by a new type of strain, the ESBL producers.
The incidence of ESBL-producing strains among clinical Klebsiella isolates has been steadily increasing over the past several
years. Frequencies of up to 40% have been reported in certain
regions. Currently, the available data suggest a further increase
in the incidence of ESBL-producing isolates. As a result, the
therapeutic options are becoming limited, so that in the near
future there will be an urgent need for hospital infection control measures that counter the spread of ESBL-producing bacteria.
(iii) Until recently, K. pneumoniae and K. oxytoca have been
considered to be the only pathogenic Klebsiella species. However, the newer species K. terrigena and K. planticola, formerly
regarded as environmental Klebsiella species, have been dem-

598

PODSCHUN AND ULLMAN

onstrated to occur in human clinical specimens. K. planticola,

in particular, has been isolated with astonishing frequency
from human infectious processes. So far, it is unclear what kind
of pathogenicity factors K. planticola might possess or whether
this species expresses the same factors that have been described for K. pneumoniae. K. planticola can, however, be expected to be of clinical significance, and the question remains
whether the identification of this species by standard laboratory procedures should be recommended.
Nosocomial Klebsiella infections continue to be a heavy burden on the economy and on the life expectancy of patients in
developed countries. Hospital infection prevention and control
programs led in the past to considerable improvements in the
management and control of these infections. However, there is
a general agreement that further progress in prevention of
hospital-acquired infections will require new approaches to
infection control. As a future challenge for the advancement of
preventive measures against nosocomial Klebsiella infections,
the usefulness of new concepts needs to be evaluated. A number of different approaches are conceivable.
One possible measure is the vaccination of persons at risk.
Regardless of whether active or passive immunization is performed (the latter preferentially by a cocktail of monoclonal
anti-Klebsiella antibodies), the question has to be raised about
whom to vaccinate. While little controversy is to be expected
for vaccinating immunocompromised hospitalized patients to
prevent fatal Klebsiella pneumonia and septicemia, the justification of immunological measures in other patient groups is
being debated. A good example in this respect is Klebsiella UTI
in elderly individuals. Most cases of bacterial pyelonephritis
are not caused by Klebsiella but by E. coli strains. However,
although Klebsiella species are not a predominant cause of
UTI, they can cause significant renal scarring even after a single episode of infection. Moreover, infections with these uropathogens are more likely to lead to death than are infections
with most E. coli strains. The question whether a Klebsiella
vaccine should be recommended for persons older than 60
years has to be clarified by cost-benefit analyses.
Another point of interest is the possible eradication of klebsiellae in patients during their hospital stay. One of the new
approaches is the use of cranberry juice. This juice shows a
pronounced anti-adhesive effect on enterobacteria and therefore might prevent colonization of hospitalized patients or
even eradicate these bacteria in colonized persons. Cranberry
juice might be of benefit both because of its high content
of fructose as an inhibitor of type 1 pili and because of the
presence of a high-molecular-weight constituent that blocks
mannose-resistant adhesion (165). It has been postulated that
the juice acts on the gastrointestinal organisms to eliminate the
source of infection rather than on the bladder because recurrent but not acute UTIs were prevented (10). Daily consumption of cranberry juice cocktail has been demonstrated to cause
bacteriuric elderly persons to become and remain abacteriuric.
The use of cranberry juice cocktail in the hospital setting might
be a paradigm for cheap and simple preventive intervention
without the use of antibiotics or vaccines.
Fascinating future aspects are also raised by new findings on
so far unknown host defense mechanisms. As mentioned above,
lung SP-A increases phagocytosis of Klebsiella by acting as an
opsonin and by activating alveolar macrophages. Another surfactant protein (SP-D) has been reported to interact with bacterial LPS. It has been suggested that SP-D plays an important
role in the defense of the lungs against gram-negative bacteria.
Investigations in the near future will show whether surfactant
proteins may be useful in new therapeutic approaches and

CLIN. MICROBIOL. REV.

whether they are a meaningful addition to the management of

nosocomial Klebsiella infections.
REFERENCES
1. Aguilar, A., S. Merino, X. Rubires, and J. M. Tomas. 1997. Influence of
osmolarity on lipopolysaccharides and virulence of Aeromonas hydrophila
serotype O:34 strains grown at 37C. Infect. Immun. 65:12451250.
2. Albert, S., D. Alvarez, S. Merino, M. T. Casado, F. Vivanco, J. M. Toma
s,
and V. J. Bened. 1996. Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae. Infect. Immun. 64:47264732.
3. Albert, S., G. Marques, S. Camprubi, S. Merino, J. M. Toma
s, F. Vivanco,
and V. J. Bened. 1993. C1q binding and activation of the complement
classical pathway by Klebsiella pneumoniae outer membrane proteins. Infect. Immun. 61:852860.
4. Albesa, I. 1989. Klebsiella pneumoniae haemolysin adsorption to red blood
cells. J. Appl. Bacteriol. 67:263266.
5. Albesa, I., L. I. Barberis, M. C. Pa
jaro, and A. J. Eraso. 1985. Actividad
hemoltica de Klebsiella pneumoniae sobre glo
bulos rojos de conejo. Rev.
Latinoam. Microbiol. 27:8387.
6. Albesa, I., L. I. Barberis, M. C. Pajaro, M. C. Farnochi, and A. J. Eraso.
1985. A thiol-activated hemolysin in gram-negative bacteria. Can. J. Microbiol. 31:297300.
7. Amako, K., Y. Meno, and A. Takade. 1988. Fine structures of the capsules
of Klebsiella pneumoniae and Escherichia coli K1. J. Bacteriol. 170:4960
4962.
8. Arlet, G., M. Rouveau, I. Casin, P. J. M. Bouvet, P. H. Lagrange, and A.
Philippon. 1994. Molecular epidemiology of Klebsiella pneumoniae strains
that produce SHV-4 b-lactamase and which were isolated in 14 french
hospitals. J. Clin. Microbiol. 32:25532558.
9. Athamna, A., I. Ofek, Y. Keisari, S. Markowitz, D. G. G. S., and N. Sharon.
1991. Lectinophagocytosis of encapsulated Klebsiella pneumoniae mediated
by surface lectins of guinea pig alveolar macrophages and human monocyte-derived macrophages. Infect. Immun. 59:16731682.
10. Avorn, J., M. Monane, J. H. Gruwitz, J. Glynn, I. Choodnovskiy, and L. A.
Lipsitz. 1994. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 271:751754.
11. Ayars, G. H., L. C. Altman, and M. D. Fretwell. 1982. Effect of decreased
salivation and pH on the adherence of Klebsiella species to human buccal
epithelial cells. Infect. Immun. 38:179182.
12. Ayling-Smith, B., and T. L. Pitt. 1990. State of the art in typing: Klebsiella
spp. J. Hosp. Infect. 16:287295.
13. Babu, J. P., S. N. Abraham, M. K. Dabbous, and E. H. Beachey. 1986.
Interaction of a 60-Kilodalton D-mannose-containing salivary glycoprotein
with type 1 fimbriae of Escherichia coli. Infect. Immun. 54:104108.
14. Bagley, S., R. J. Seidler, and D. J. Brenner. 1981. Klebsiella planticola sp.
nov.: a new species of Enterobacteriaceae found primarily in nonclinical
environments. Curr. Microbiol. 6:105109.
15. Bagley, S. T., R. J. Seidler, H. W. J. Talbot, and J. E. Morrow. 1978.
Isolation of Klebsiellae from within living wood. Appl. Environ. Microbiol.
36:178185.
16. Balish, M. J., J. Jensen, and D. T. Uehling. 1982. Bladder mucin: a scanning
electron microscopy study in experimental cystitis. J. Urol. 128:10601063.
17. Barberis, L. I., A. J. Eraso, M. C. Pa
jaro, and I. Albesa. 1986. Molecular
weight determination and partial characterization of Klebsiella pneumoniae
hemolysins. Can. J. Microbiol. 32:884888.
18. Bascomb, S., S. P. Lapage, W. R. Willcox, and M. A. Curtis. 1971. Numerical classification of the tribe Klebsiellae. J. Gen. Microbiol. 66:279295.
19. Batshon, B. A., H. Baer, and M. F. Shaffer. 1963. Immunologic paralysis
produced in mice by Klebsiella pneumoniae type 2 polysaccharide. J. Immunol. 90:121126.
20. Bauernfeind, A. 1984. Epidemiological typing of Klebsiella by bacteriocins.
Methods Microbiol. 16:213224.
21. Bauernfeind, A., C. Petermu
ller, and R. Schneider. 1981. Bacteriocins as
tools in analysis of nosocomial Klebsiella pneumoniae infections. J. Clin.
Microbiol. 14:1519.
22. Bauernfeind, A., E. Rosenthal, E. Eberlein, M. Holley, and S. Schweighart.
1993. Spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase
among hospitalized patients. Infection 21:1822.
23. Benjamin, W. H., C. L. Turnbough, B. S. Posey, and D. E. Briles. 1985. The
ability of Salmonella typhimurium to produce the siderophore enterobactin
is not a virulence factor in mouse typhoid. Infect. Immun. 50:392397.
24. Bennet, R., M. Eriksson, B. Melen, and R. Zetterstrom. 1985. Changes in
the incidence and spectrum of neonatal septicemia during a fifteen-year
period. Acta Paediatr. Scand. 74:687690.
25. Bennett, C. J., M. N. Young, and H. Darrington. 1995. Differences in
urinary tract infection in male and female spinal cord injury patients on
intermittent catheterization. Paraplegia 33:6972.
26. Bergogne-Berezin, E. 1995. Nosocomial pathogens: new pathogens, incidence, prevention. Presse Med. 24:8997.
27. Bingen, E. H., E. Denamur, and J. Elion. 1994. Use of ribotyping in epidemiological surveillance of nosocomial outbreaks. Clin. Microbiol. Rev. 7:
311327.

VOL. 11, 1998

28. Bingen, E. H., P. Desjardins, G. Arlet, F. Bourgeois, P. Marianikurkdjian,
N. Y. Lambertzechovsky, E. Denamur, A. Philippon, and J. Elion. 1993.
Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric
hospital. J. Clin. Microbiol. 31:179184.
29. Bjo
rksten, B., and B. Kaijser. 1978. Interaction of human serum and neutrophils with Escherichia coli strains: differences between strains isolated
from urine of patients with pyelonephritis or asymptomatic bacteriuria.
Infect. Immun. 22:308311.
30. Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and
K. Bush. 1997. Imipenem resistance in Klebsiella pneumoniae is associated
with the combination of ACT-1, a plasmid-mediated AmpC b-lactamase,
and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563569.
31. Brenner, D. J., J. J. Farmer III, F. W. Hickman, M. A. Asbury, and A. G.
Steigerwalt. 1977. Taxonomic and nomenclature changes in Enterobacteriaceae. HEW publication (CDC) 79-8356. Centers for Disease Control,
Atlanta, Ga.
32. Brock, J. H., P. H. Williams, J. Liceaga, and K. G. Wooldridge. 1991.
Relative availability of transferrin-bound iron and cell-derived iron to aerobactin-producing and enterobactin-producing strains of Escherichia coli and
to other microorganisms. Infect. Immun. 59:31853190.
33. Brown, C., and R. J. Seidler. 1973. Potential pathogens in the environment:
Klebsiella pneumoniae, a taxonomic and ecological enigma. Appl. Microbiol. 25:900904.
34. Bryan, C. S., C. A. Hornung, K. L. Reynolds, and E. R. Brenner. 1986.
Endemic bacteremia in Columbia, South Carolina. Am. J. Epidemiol. 123:
113127.
35. Bryan, C. S., K. L. Reynolds, and E. R. Brenner. 1983. Analysis of 1,186
episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev. Infect. Dis. 5:629638.
36. Buffenmeyer, C. L., R. R. Rychek, and R. B. Yee. 1976. Bacteriocin (klebocin) sensitivity typing of Klebsiella. J. Clin. Microbiol. 4:239244.
37. Bullen, J. J., H. J. Rogers, and E. Griffiths. 1978. Role of iron in bacterial
infection. Curr. Top. Microbiol. Immunol. 80:135.
38. Burwen, D. R., S. N. Banerjee, and R. P. Gaynes. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United
States. J. Infect. Dis. 170:16221625.
39. Campbell, W. N., E. Hendrix, S. Cryz, and A. S. Cross. 1996. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eightvalent Pseudomonas O-polysaccharide conjugate vaccine administered to
victims of acute trauma. Clin. Infect. Dis. 23:179181.
40. Carpenter, J. L. 1990. Klebsiella pulmonary infections: occurrence at one
medical center and review. Rev. Infect. Dis. 12:672682.
41. Casewell, M., and H. G. Talsania. 1979. Predominance of certain klebsiella
capsular types in hospitals in the United Kingdom. J. Infect. 1:7779.
42. Casewell, M. W., and I. Phillips. 1978. Epidemiological patterns of klebsiella colonization and infection in an intensive care ward. J. Hyg. Camb. 80:
295300.
43. Casewell, M. W., and I. Phillips. 1977. Hands as a route of transmission for
Klebsiella species. Br. Med. J. 2:13151317.
44. Centers for Disease Control. 1985. National nosocomial infections study
report. Annual Summary 1983, p. 9SS21SS. Centers for Disease Control,
Atlanta, Ga.
45. Centers for Disease Control. 1977. National nosocomial infections study
report. Annual Summary 1975. Centers for Disease Control, Atlanta, Ga.
46. Centers for Disease Control. 1982. National nosocomial infections study
report. Annual Summary 1979. Centers for Disease Control, Atlanta, Ga.
47. Centers for Disease Control. 1984. Nosocomial infection surveillance, 1983.
CDC Surveillance Summaries 33:95522SS.
48. Christensen, S. C., and B. Korner. 1972. An endemic caused by multiresistant Klebsiella in an urological unit. Scand. J. Urol. Nephrol. 6:232238.
49. Ciurana, B., and J. M. Toma
s. 1987. Role of lipopolysaccharide and complement in susceptibility of Klebsiella pneumoniae to nonimmune serum.
Infect. Immun. 55:27412746.
50. Clegg, S., and G. F. Gerlach. 1987. Enterobacterial fimbriae. J. Bacteriol.
169:934938.
51. Combe, M. L., J. L. Pons, R. Sesboue, and J. P. Martin. 1994. Electrophoretic transfer from polyacrylamide gel to nitrocellulose sheets: a new
method to characterize multilocus enzyme genotypes of Klebsiella strains.
Appl. Environ. Microbiol. 60:2630.
52. Cooke, E. M., R. Pool, J. C. Brayson, A. S. Edmondson, M. E. Munro, and
R. Shinebaum. 1979. Further studies on the source of Klebsiella aerogenes in
hospital patients. J. Hyg. Camb. 83:391395.
53. Coovadia, Y. M., A. P. Johnson, R. H. Bhana, G. R. Hutchinson, R. C.
George, and I. E. Hafferjee. 1992. Multiresistant Klebsiella pneumoniae in a
neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks. J. Hosp. Infect. 22:197
205.
54. Cowan, S. T., K. J. Steel, C. Shaw, and J. P. Duguid. 1960. A classification
of the Klebsiella group. J. Gen. Microbiol. 23:601612.

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

599

55. Cryz, S. J. 1983. Progress in immunization against Klebsiella infections. Eur.

J. Clin. Microbiol. 2:523528.
56. Cryz, S. J., E. Fu
rer, and R. Germanier. 1984. Experimental Klebsiella
pneumoniae burn wound sepsis: role of capsular polysaccharide. Infect.
Immun. 43:440441.
57. Cryz, S. J., Jr., E. Fu
rer, and R. Germanier. 1985. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J. Infect. Dis. 151:665671.
58. Cryz, S. J., Jr., P. Mortimer, A. S. Cross, E. Fu
rer, and R. Germanier. 1986.
Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 4:1520.
59. Cryz, S. J., P. M. Mortimer, V. Mansfield, and R. Germanier. 1986. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine
development. J. Clin. Microbiol. 23:687690.
60. Curie, K., D. C. E. Speller, R. A. Simpson, M. Stephens, and D. I. Cooke.
1978. A hospital epidemic caused by a gentamicin-resistant Klebsiella aerogenes. J. Hyg. Camb. 80:115123.
61. Darfeuille-Michaud, A., C. Jallat, D. Aubel, D. Sirot, C. Rich, J. Sirot, and
B. Joly. 1992. R-plasmid-encoded adhesive factor in Klebsiella pneumoniae
strains responsible for human nosocomial infections. Infect. Immun. 60:44
45.
62. Davis, T. J., and J. M. Matsen. 1974. Prevalence and characteristics of
Klebsiella species: relation to association with a hospital environment. J. Infect. Dis. 130:402405.
63. De Champs, C., D. Rouby, D. Guelon, J. Sirot, D. Sirot, D. Beytout, and
J. M. Gourgand. 1991. A case-control study of an outbreak of infections
caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) betalactamase. J. Hosp. Infect. 18:513.
64. de la Torre, M. G., J. Romero-Vivas, J. Martinez-Beltran, A. Guerrero, M.
Meseguer, and E. Bouza. 1985. Klebsiella bacteremia: an analysis of 100
episodes. Rev. Infect. Dis. 7:143150.
65. de Lorenzo, V., and J. L. Martinez. 1988. Aerobactin production as a
virulence factor: a reevaluation. Eur. J. Clin. Microbiol. Infect. Dis. 7:621
629.
66. Di Martino, P., Y. Bertin, P. Girardeau, V. Livrelli, B. Joly, and A. Darfeuille-Michaud. 1995. Molecular characterization and adhesive properties
of CF29K, an adhesin of Klebsiella pneumoniae strains involved in nosocomial infections. Infect. Immun. 63:43364344.
67. Di Martino, P., V. Livrelli, D. Sirot, B. Joly, and A. Darfeuille-Michaud.
1996. A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections. Infect. Immun.
64:22662273.
68. Doebbeling, B. N. 1993. Epidemics: identification and management, p. 177
206. In R. P. Wenzel (ed.), Prevention and control of nosocomial infections,
2nd ed. The Williams & Wilkins Co., Baltimore, Md.
69. Domenico, P., W. G. Johanson, and D. C. Straus. 1982. Lobar pneumonia
in rats produced by clinical isolates of Klebsiella pneumoniae. Infect. Immun. 37:327335.
70. Duggan, J. M., G. S. Oldfield, and H. K. Ghosh. 1985. Septicaemia as a
hospital hazard. J. Hosp. Infect. 6:406412.
71. Edberg, S. C., V. Piscitelli, and M. Cartter. 1986. Phenotypic characteristics
of coliform and noncoliform bacteria from a public water supply compared
with regional and national clinical species. Appl. Environ. Microbiol. 52:
474478.
72. Edelman, R., D. N. Taylor, S. S. Wasserman, J. B. Mcclain, A. S. Cross,
J. C. Sadoff, J. U. Que, and S. J. Cryz. 1994. Phase 1 trial of a 24-valent
Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 12:12881294.
73. Edmondson, A. S., and E. M. Cooke. 1979. The development and assessment of a bacteriocin typing method for Klebsiella. J. Hyg. Camb. 82:207
233.
74. Edmondson, A. S., E. M. Cooke, A. P. D. Wilcock, and R. Shinebaum. 1980.
A comparison of the properties of Klebsiella strains isolated from different
sources. J. Med. Microbiol. 13:541550.
75. Edwards, P. R., and W. H. Ewing. 1986. Identification of Enterobacteriaceae,
4th ed. Burgess Publishing Co., Minneapolis, Minn.
76. Ehrenwort, L., and H. Baer. 1956. The pathogenicity of Klebsiella pneumoniae for mice: the relationship to the quantity and rate of production of
type-specific capsular polysaccharide. J. Bacteriol. 72:713717.
77. Fader, R. C., and C. P. Davis. 1980. Effect of piliation on Klebsiella pneumoniae infection in rat bladders. Infect. Immun. 30:554561.
78. Fader, R. C., and C. P. Davis. 1982. Klebsiella pneumoniae-induced experimental pyelitis: the effect of piliation on infectivity. J. Urol. 128:197201.
79. Farmer, J. J., III, B. R. Davis, F. W. Hickman-Brenner, A. McWhorter,
G. P. Huntley-Carter, M. A. Asbury, C. Riddle, H. G. Wathen-Grady, C.
Elias, G. R. Fanning, A. G. Steigerwalt, C. M. OHara, G. K. Morris, P. B.
Smith, and D. J. Brenner. 1985. Biochemical identification of new species
and biogroups of Enterobacteriaceae isolated from clinical specimens.
J. Clin. Microbiol. 21:4676.
80. Favre-Bonte, S., A. Darfeuille-Michaud, and C. Forestier. 1995. Aggrega-

600

81.
82.
83.
84.
85.

86.

87.
88.
89.
90.
91.

92.
93.
94.

95.

96.
97.
98.
99.

100.
101.

102.
103.
104.
105.
106.

PODSCHUN AND ULLMAN

tive adherence of Klebsiella pneumoniae to human Intestine-407 cells. Infect. Immun. 63:13181328.
Felson, B., L. S. Rosenberg, and M. J. Hamburger. 1949. Roentgen findings
in acute Friedlanders pneumonia. Radiology 53:559565.
Ferragut, C., D. Izard, F. Gavini, K. Kersters, J. De Ley, and H. Leclerc.
1983. Klebsiella trevisanii: a new species from water and soil. Int. J. Syst.
Bacteriol. 33:133142.
Firon, N., I. Ofek, and N. Sharon. 1984. Carbohydrate-binding sites of the
mannose-specific fimbrial lectins of enterobacteria. Infect. Immun. 43:
10881090.
Freedman, R. M., D. L. Ingram, I. Gross, R. A. Ehrenkranz, J. B. Warshaw,
and R. S. Baltimore. 1981. A half century of neonatal sepsis at Yale. Am. J.
Dis. Child 135:140144.
French, G. L., K. P. Shannon, and N. Simmons. 1996. Hospital outbreak of
Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and
b-lactamb-lactamase inhibitor combinations by hyperproduction of
SHV-5 b-lactamase. J. Clin. Microbiol. 34:358363.
Gavini, F., D. Izard, P. A. D. Grimont, A. Beji, E. Ageron, and H. Leclerc.
1986. Priority of Klebsiella planticola Bagley, Seidler, and Brenner 1982 over
Klebsiella trevisanii Ferragut, Izard, Gavini, Kersters, DeLey, and Leclerc
1983. Int. J. Syst. Bacteriol. 36:486488.
Gavini, F., H. Leclerc, B. Lefe`bvre, C. Ferragut, and D. Izard. 1977. Etude
taxonomique denterobacteries appartenant ou apparente
es au genre Klebsiella. Ann. Microbiol. (Inst Pasteur). 128B:4549.
Gerlach, G. F., B. L. Allen, and S. Clegg. 1989. Type 3 fimbriae among
enterobacteria and the ability of spermidine to inhibit MR/K hemagglutination. Infect. Immun. 57:219224.
Goetz, A. M., J. D. Rihs, J. W. Chow, N. Singh, and R. R. Muder. 1995. An
outbreak of infusion-related Klebsiella pneumoniae bacteremia in a liver
transplantation unit. Clin. Infect. Dis. 21:15011503.
Gotoff, S. P. 1992. Sepsis in the newborn, p. 402418. In S. Krugman, S. L.
Katz, A. A. Gershon, and C. M. Wilfert (ed.), Infectious diseases of children, 9th ed. MosbyYear Book, St. Louis, Mo.
Gouby, A., C. Neuwirth, G. Bourg, N. Bouziges, M. J. Carlesnurit, E.
Despaux, and M. Ramuz. 1994. Epidemiological study by pulsed-field gel
electrophoresis of an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a geriatric hospital. J. Clin. Microbiol. 32:
301305.
Gower, P. E., P. W. Taylor, K. G. Koutsaimanis, and A. P. Roberts. 1972.
Serum bactericidal activity in patients with upper and lower urinary tract
infections. Clin. Sci. 43:1322.
Griffiths, E. 1987. The iron-uptake systems of pathogenic bacteria, p. 69
137. In J. J. Bullen and E. Griffiths (ed.), Iron and infection. John Wiley &
Sons, Inc., New York, N.Y.
Griffiths, E., H. Chart, and P. Stevenson. 1988. High-affinity iron uptake
systems and bacterial virulence, p. 121137. In J. A. Roth (ed.), Virulence
mechanisms of bacterial pathogens. American Society for Microbiology,
Washington, D.C.
Guarino, A., S. Guandalini, M. Alessio, F. Gentile, L. Tarallo, G. Capano,
M. Migliavacca, and A. Rubino. 1989. Characteristics and mechanism of
action of a heat-stable enterotoxin produced by Klebsiella pneumoniae from
infants with secretory diarrhea. Pediatr. Res. 25:514518.
Gu
r, D., T. L. Pitt, L. M. C. Hall, H. Erdal Akalin, and D. M. Livermore.
1992. Diversity of klebsiellae with extended-spectrum b-lactamases at a
turkish university hospital. J. Hosp. Infect. 22:163178.
Hall, F. A. 1971. Bacteriocine typing of Klebsiella spp. J. Clin. Pathol. 24:
712716.
Hart, C. A. 1993. Klebsiellae and neonates. J. Hosp. Infect. 23:8386.
Hartstein, A. I., V. H. Morthland, J. W. Rourke, R. Sykes, and A. L. Rashad.
1993. Plasmid DNA analysis, biotyping, and antimicrobic susceptibility as
subtyping tests for Klebsiella pneumoniae and Klebsiella oxytoca. Diagn.
Microbiol. Infect. Dis. 16:3541.
Haverkorn, M. L., and M. F. Michel. 1979. Nosocomial klebsiellas I. Colonization of hospitalized patients. J. Hyg. Camb. 82:177193.
Hibbertrogers, L. C. F., J. Heritage, D. M. Gascoynebinzi, P. M. Hawkey, N.
Todd, I. J. Lewis, and C. Bailey. 1995. Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology
ward. J. Antimicrob. Chemother. 36:6582.
Higaki, M., T. Chida, H. Takano, and R. Nakaya. 1990. Cytotoxic component(s) of Klebsiella oxytoca on HEp-2 cells. Microbiol. Immunol. 34:147
151.
Highsmith, A. K., and W. R. Jarvis. 1985. Klebsiella pneumoniae: selected
virulence factors that contribute to pathogenicity. Infect. Control 6:7577.
Horan, T., D. Culver, W. Jarvis, G. Emori, S. Banerjee, W. Martone, and C.
Thornsberry. 1988. Pathogens causing nosocomial infections. Antimicrobic
Newsl. 5:6567.
Hornick, D. B., B. L. Allen, M. A. Horn, and S. Clegg. 1992. Adherence to
respiratory epithelia by recombinant Escherichia coli expressing Klebsiella
pneumoniae type 3 fimbrial gene products. Infect. Immun. 60:15771588.
Iwahi, T., Y. Abe, M. Nakao, A. Imada, and K. Tsuchiya. 1983. Role of type
1 fimbriae in the pathogenesis of ascending urinary tract infection induced
by Escherichia coli. Infect. Immun. 39:13071315.

CLIN. MICROBIOL. REV.

107. Izard, D., C. Ferragut, F. Gavini, K. Kersters, J. De Ley, and H. Leclerc.
1981. Klebsiella terrigena, a new species from soil and water. Int. J. Syst.
Bacteriol. 31:116127.
108. Jacoby, G. A. 1996. Antimicrobial-resistant pathogens in the 1990s. Annu.
Rev. Med. 47:169179.
109. Jacoby, G. A., and P. Han. 1996. Detection of extended-spectrum b-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
J. Clin. Microbiol. 34:908911.
110. Jain, K., K. Radsak, and W. Mannheim. 1974. Differentiation of the oxytocum group from Klebsiella by deoxyribonucleic acid-deoxyribonucleic acid
hybridization. Int. J. Syst. Bacteriol. 24:402407.
111. Jarlier, V., M. H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended
broad-spectrum b-lactamases conferring transferable resistance to newer
b-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867878.
112. Johanson, W. G., A. K. Pierce, and J. P. Sanford. 1969. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative
bacilli. N. Engl. J. Med. 281:11371140.
113. Johnson, A. P., M. J. Weinbren, B. Ayling-Smith, S. K. Du Bois, S. G. B.
Amyes, and R. C. George. 1992. Outbreak of infection in two UK hospitals
caused by a strain of Klebsiella pneumoniae resistant to cefotaxime and
ceftazidime. J. Hosp. Infect. 20:97103.
114. Joiner, K. A. 1988. Complement evasion by bacteria and parasites. Annu.
Rev. Microbiol. 42:201230.
115. Jones, G. W., and R. E. Isaacson. 1983. Proteinaceous bacterial adhesins
and their receptors. Crit. Rev. Microbiol. 10:229260.
116. Jumaa, P., and B. Chattopadhyay. 1992. Pseudobacteraemia with multiplyresistant Klebsiella pneumoniae resulting from contamination from the
blood gas machine on a neonatal unit. J. Hosp. Infect. 22:251255.
117. Kabha, K., L. Nissimov, A. Athamna, Y. Keisari, H. Parolis, L. A. S.
Parolis, R. M. Grue, J. Schlepper-Shafer, A. R. B. Ezekowitz, D. E. Ohman,
and I. Ofek. 1995. Relationships among capsular structure, phagocytosis,
and mouse virulence in Klebsiella pneumoniae. Infect. Immun. 63:847852.
118. Kabha, K., J. Schmegner, Y. Keisari, H. Parolis, J. Schlepper-Schaefer, and
I. Ofek. 1997. SP-A enhances phagocytosis of Klebsiella by interaction with
capsular polysaccharides and alveolar macrophages. Am. J. Physiol. 272:
L344L352.
119. Katsanis, G. P., J. Spargo, M. J. Ferraro, L. Sutton, and G. A. Jacoby. 1994.
Detection of Klebsiella pneumoniae and Escherichia coli strains producing
extended-spectrum b-lactamases. J. Clin. Microbiol. 32:691696.
120. Kauffmann, F. 1949. On the serology of the Klebsiella group. Acta Pathol.
Scand. 26:381406.
121. Khimji, P. L., and A. A. Miles. 1978. Microbial iron-chelators and their
action on Klebsiella infections in the skin of guinea-pigs. Br. J. Exp. Pathol.
59:137147.
122. Klipstein, F. A., and R. F. Engert. 1975. Enterotoxigenic intestinal bacteria
in tropical sprue. III. Preliminary characterization of Klebsiella pneumoniae
enterotoxin. J. Infect. Dis. 132:200203.
123. Klipstein, F. A., and R. F. Engert. 1977. Immunological interrelationships
between cholera toxin and the heat-labile and heat-stable enterotoxins of
coliform bacteria. Infect. Immun. 18:110117.
124. Klipstein, F. A., and R. F. Engert. 1976. Purification and properties of
Klebsiella pneumoniae heat-stable enterotoxin. Infect. Immun. 13:373381.
125. Klipstein, F. A., R. F. Engert, and R. A. Houghten. 1983. Immunological
properties of purified Klebsiella pneumoniae heat-stable enterotoxin. Infect.
Immun. 42:838841.
126. Kloos, W. E., and M. S. Musselwhite. 1975. Distribution and persistence of
Staphylococcus and Micrococcus species and other aerobic bacteria on human skin. Appl. Microbiol. 30:381395.
127. Koo, F. C. W., and M. D. Stein. 1986. Detection of an extracellular toxin
produced by burn isolates of Klebsiella pneumoniae. Curr. Microbiol. 13:23
27.
128. Korhonen, T. K., E. Tarkka, H. Ranta, and K. Haahtela. 1983. Type 3
fimbriae of Klebsiella sp.: molecular characterization and role in bacterial
adhesion to plant roots. J. Bacteriol. 155:860865.
129. Ku
hn, I., B. Ayling-Smith, K. Tullus, and L. G. Burman. 1993. The use of
colonization rate and epidemic index as tools to illustrate the epidemiology
of faecal Enterobacteriaceae strains in Swedish neonatal wards. J. Hosp.
Infect. 23:287297.
130. Legakis, N. J., A. Maniatis, and L. S. Tzouvelekis. 1995. Prevalent mechanisms of resistance among common enterobacterial isolates in Greek hospitals. Microb. Drug Resist. 1:331333.
131. Lock, R., C. Dahlgren, M. Linden, O. Stendahl, A. Svensbergh, and L.
hman. 1990. Neutrophil killing of two type 1 fimbria-bearing Escherichia
O
coli strains: dependence on respiratory burst activation. Infect. Immun. 58:
3742.
132. Lucet, J. C., S. Chevret, D. Decre, D. Vanjak, A. Macrez, J. P. Bedos, M.
Wolff, and B. Regnier. 1996. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: Epidemiology and risk factors for acquisition. Clin. Infect. Dis. 22:430436.
133. Lye, W. C., R. K. T. Chan, E. J. C. Lee, and G. Kumarasinghe. 1992.

VOL. 11, 1998

134.
135.
136.

137.
138.
139.
140.
141.
142.
143.

144.
145.
146.
147.
148.
149.
150.
151.
152.

153.
154.
155.

156.
157.

158.

Urinary tract infections in patients with diabetes mellitus. J. Infect. 24:169

174.
Maayan, M. C., I. Ofek, O. Medalia, and M. Aronson. 1985. Population
shift in mannose-specific fimbriated phase of Klebsiella pneumoniae during
experimental urinary tract infection in mice. Infect. Immun. 49:785789.
Maki, D. G. 1981. Epidemic nosocomial bacteremias, p. 371512. In R. P.
Wenzel (ed.), CRC Handbook of hospital acquired infections. CRC Press,
Inc., Boca Raton, Fla.
Mandine, E., M. F. Salles, R. Zalisz, M. Guenounou, and P. Smets. 1990.
Murine monoclonal antibodies to Klebsiella pneumoniae protect against
lethal endotoxemia and experimental infection with capsulated K. pneumoniae. Infect. Immun. 58:28282833.
Mangan, D. F., and I. S. Snyder. 1979. Mannose-sensitive stimulation of
human leucocyte chemiluminescence by Escherichia coli. Infect. Immun. 26:
10141019.
Martin, C. M., N. S. Ikari, J. Zimmerman, and J. A. Waitz. 1971. A virulent
nosocomial Klebsiella with a transferable R factor for gentamicin: emergence and suppression. J. Infect. Dis. 124(Suppl.):S24S29.
Martinez, J. L., E. Cercenado, F. Baquero, J. C. Perez-Daz, and A. Delgado-Iribarren. 1987. Incidence of aerobactin production in gram-negative
hospital isolates. FEMS Microbiol. Lett. 43:351353.
Matsen, J. M., J. A. Spindler, and R. O. Blosser. 1974. Characterization of
Klebsiella isolates from natural receiving waters and comparison with human isolates. Appl. Microbiol. 28:672678.
Matsumoto, T., Y. Mizunoe, N. Sakamoto, M. Tanaka, and J. Kumazawa.
1990. Increased renal scarring by bacteria with mannose-sensitive pili. Urol.
Res. 18:299303.
Mayhall, C. G. 1987. Surgical infections including burns, p. 614664. In
R. P. Wenzel (ed.), Prevention and control of nosocomial infections, 2nd
ed. The Williams & Wilkins Co., Baltimore, Md.
McCallum, K. L., G. Schoenhals, D. Laakso, B. Clarke, and C. Whitfield.
1989. A high-molecular-weight fraction of smooth lipopolysaccharide in
Klebsiella serotype O1:K20 contains a unique O-antigen epitope and determines resistance to nonspecific serum killing. Infect. Immun. 57:38163822.
Medeiros, A. A. 1993. Nosocomial outbreaks of multiresistant bacteria
extended-spectrum beta-lactamases have arrived in North America. Ann.
Intern. Med. 119:428430.
Merino, S., S. Camprub, S. Albert, V. J. Bened, and J. M. Toma
s. 1992.
Mechanisms of Klebsiella pneumoniae resistance to complement-mediated
killing. Infect. Immun. 60:25292535.
Meyer, K. S., C. Urban, J. A. Eagan, B. J. Berger, and J. J. Rahal. 1993.
Nosocomial outbreak of Klebsiella infection resistant to late-generation
cephalosporins. Ann. Intern. Med. 119:353358.
Miles, A. A., and P. L. Khimji. 1975. Enterobacterial chelators of iron: their
occurrence, detection, and relation to pathogenicity. J. Med. Microbiol. 8:
477490.
Minami, J., S. I. Katayama, O. Matsushita, H. Sakamoto, and A. Okabe.
1994. Enterotoxic activity of Klebsiella oxytoca cytotoxin in rabbit intestinal
loops. Infect. Immun. 62:172177.
Minami, J., A. Okabe, J. Shiode, and H. Hayashi. 1989. Production of a
unique cytotoxin by Klebsiella oxytoca. Microb. Pathog. 7:203211.
Minami, J., S. Saito, T. Yoshida, T. Uemura, and A. Okabe. 1992. Biological
activities and chemical composition of a cytotoxin of Klebsiella oxytoca.
J. Gen. Microbiol. 138:19211927.
Mizuta, K., M. Ohta, M. Mori, T. Hasegawa, I. Nakashima, and N. Kato.
1983. Virulence for mice of Klebsiella strains belonging to the O1 group:
relationship to their capsule (K) types. Infect. Immun. 40:5661.
Mobley, H. L. T., G. R. Chippendale, J. H. Tenney, A. R. Mayrer, L. J.
Crisp, J. L. Penner, and J. W. Warren. 1988. MR/K hemagglutination of
Providencia stuartii correlates with adherence to catheters and with persistence in catheter-associated bacteriuria. J. Infect. Dis. 157:264271.
Monnet, D., and J. Freney. 1994. Method for differentiating Klebsiella
planticola and Klebsiella terrigena from other Klebsiella species. J. Clin.
Microbiol. 32:11211122.
Monnet, D., J. Freney, Y. Brun, J. M. Boeufgras, and J. Fleurette. 1991.
Difficulties in identifying Klebsiella strains of clinical origin. Zentbl. Bakteriol. 274:456464.
Montenegro, M. A., D. Bitter-Suermann, J. K. Timmis, M. E. Agu
ero, F. C.
Cabello, S. C. Sanyal, and K. N. Timmis. 1985. TraT gene sequences, serum
resistance and pathogenicity-related factors in clinical isolates of Escherichia coli and other gram-negative bacteria. J. Gen. Microbiol. 131:1511
1521.
Montgomerie, J. Z. 1979. Epidemiology of Klebsiella and hospital-associated infections. Rev. Infect. Dis. 1:736753.
Montgomerie, J. Z., J. F. John, L. M. Atkins, D. S. Gilmore, and M. A.
Ashley. 1993. Increased frequency of large R-plasmids in Klebsiella pneumoniae colonizing patients with spinal cord injury. Diagn. Microbiol. Infect.
Dis. 16:2529.
Mori, M., M. Ohta, N. Agata, N. Kido, Y. Arakawa, H. Ito, T. Komatsu, and
N. Kato. 1989. Identification of species and capsular types of Klebsiella
clinical isolates, with special reference to Klebsiella planticola. Microbiol.
Immunol. 33:887895.

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

601

159. Nassif, X., and P. J. Sansonetti. 1986. Correlation of the virulence of

Klebsiella pneumoniae K1 and K2 with the presence of a plasmid encoding
aerobactin. Infect. Immun. 54:603608.
160. Noriega, E. R., R. E. Leibowitz, A. S. Richmond, E. Rubinstein, S.
Schaefler, M. S. Simberkoff, and J. J. Rahal. 1975. Nosocomial infection
caused by gentamicin-resistant, streptomycin-sensitive Klebsiella. J. Infect.
Dis. 131(Suppl):S45S50.
161. Nouvellon, M., J. L. Pons, D. Sirot, M. L. Combe, and J. F. Lemeland. 1994.
Clonal outbreaks of extended-spectrum b-lactamase-producing strains of
Klebsiella pneumoniae demonstrated by antibiotic susceptibility testing, blactamase typing, and multilocus enzyme electrophoresis. J. Clin. Microbiol. 32:26252627.
162. Ofek, I., and E. H. Beachey. 1978. Mannose binding and epithelial cell
adherence of Escherichia coli. Infect. Immun. 22:247254.
163. Ofek, I., and R. J. Doyle. 1994. Bacterial adhesion to cells and tissues.
Chapman & Hall, Ltd., London, United Kingdom.
164. Ofek, I., J. Goldhar, and Y. Keisari. 1995. Nonopsonic phagocytosis of
microorganisms. Annu. Rev. Microbiol. 49:239276.
165. Ofek, I., J. Goldhar, D. Zafriri, H. Lis, R. Adar, and N. Sharon. 1991.
Anti-Escherichia coli adhesin activity of cranberry and blueberry juices.
N. Engl. J. Med. 324:1599.
166. Ofek, I., K. Kabha, A. Athamna, G. Frankel, D. J. Wozniak, D. L. Hasty,
and D. E. Ohman. 1993. Genetic exchange of determinants for capsular
polysaccharide biosynthesis between Klebsiella pneumoniae strains expressing serotypes K2 and K21a. Infect. Immun. 61:42084216.
167. Ofek, I., and N. Sharon. 1988. Lectinophagocytosis: a molecular mechanism
of recognition between cell surface sugars and lectins in the phagocytosis of
bacteria. Infect. Immun. 56:539547.
168. Ohlsson, A., T. Bailey, and F. Takieddine. 1986. Changing etiology and
outcome of neonatal septicemia in Riyadh, Saudi Arabia. Acta Paediatr.
Scand. 75:540544.
hman, L., K.-E. Magnusson, and O. Stendahl. 1985. Mannose-specific
169. O
and hydrophobic interaction between Escherichia coli and polymorphonuclear leucocytesinfluence of bacterial culture period. Acta Pathol. Microbiol. Immunol. Scand. Sect. B 93:125131.
170. Old, D. C., and R. A. Adegbola. 1985. Antigenic relationships among type-3
fimbriae of Enterobacteriaceae revealed by immunoelectronmicroscopy.
J. Med. Microbiol. 20:113121.
171. Old, D. C., A. Tavendale, and B. W. Senior. 1985. A comparative study of
the type-3 fimbriae of Klebsiella species. J. Med. Microbiol. 20:203214.
172. Olling, S. 1977. Sensitivity of gram-negative bacilli to the serum bactericidal
activity: a marker of the host parasite relationship in acute and persisting
infections. Scand. J. Infect. Dis. 10(Suppl.):140.
173. Opal, S., A. Cross, and P. Gemski. 1982. K antigen and serum sensitivity of
rough Escherichia coli. Infect. Immun. 37:956960.
174. rskov, I. 1984. Genus Klebsiella, p. 461465. In N. R. Krieg and J. G. Holt
(ed.), Bergeys manual of systematic bacteriology, vol. 1. The Williams &
Wilkins Co., Baltimore, Md.
175. rskov, I. 1954. O antigens in the Klebsiella group. Acta Pathol. Microbiol.
Scand. 34:145156.
176. rskov, I., and M. A. Fife-Asbury. 1977. New Klebsiella capsular antigen,
K82, and the deletion of five of those previously assigned. Int. J. Syst.
Bacteriol. 27:386387.
177. rskov, I., and F. rskov. 1984. Serotyping of Klebsiella. Methods Microbiol. 14:143164.
178. Ottow, J. C. G. 1975. Ecology, physiology, and genetics of fimbriae and pili.
Annu. Rev. Microbiol. 29:79108.
179. Pagani, L., P. Ronza, E. Giacobone, and E. Romero. 1994. Extended spectrum beta-lactamases from Klebsiella pneumoniae strains isolated at an
Italian hospital. Eur. J. Epidemiol. 10:533540.
180. Pieroni, P., R. P. Rennie, B. Ziola, and H. G. Deneer. 1994. The use of
bacteriophages to differentiate serologically cross-reactive isolates of Klebsiella pneumoniae. J. Med. Microbiol. 41:423429.
181. Pittet, D., N. Li, and R. P. Wenzel. 1993. Association of secondary and
polymicrobial nosocomial bloodstream infections with higher mortality.
Eur. J. Clin. Microbiol. Infect. Dis. 12:813819.
182. Podschun, R. 1990. Phenotypic properties of Klebsiella pneumoniae and
K. oxytoca isolated from different sources. Zentbl. Hyg. Umweltmed. 189:
527535.
183. Podschun, R., A. Fischer, and U. Ullmann. 1992. Siderophore production of
Klebsiella species isolated from different sources. Zentbl. Bakteriol. 276:
481486.
184. Podschun, R., P. Heineken, and H. G. Sonntag. 1987. Hemagglutinins and
adherence properties to HeLa and Intestine 407 cells of Klebsiella pneumoniae and Klebsiella oxytoca isolates. Zentbl. Bakteriol. Mikrobiol. Hyg.
Ser. A 263:585593.
185. Podschun, R., P. Heineken, U. Ullmann, and H. G. Sonntag. 1986. Comparative investigations of Klebsiella species of clinical origin: plasmid patterns, biochemical reactions, antibiotic resistances and serotypes. Zentbl.
Bakteriol. Mikrobiol. Hyg. Ser. A 262:335345.
186. Podschun, R., I. Penner, and U. Ullmann. 1992. Interaction of Klebsiella

602

187.
188.
189.
190.
191.
192.
193.

194.
195.
196.
197.
198.

199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.

214.

215.

PODSCHUN AND ULLMAN

capsule type 7 with human polymorphonuclear leucocytes. Microb. Pathog.
13:371379.
Podschun, R., and U. Ullmann. 1993. Bacteriocin typing of environmental
Klebsiella isolates. Zentbl. Hyg. Umweltmed. 195:2226.
Podschun, R., and U. Ullmann. 1996. Bacteriocin typing of Klebsiella spp.
isolated from different sources. Zentbl. Hyg. Umweltmed. 198:258264.
Podschun, R., and U. Ullmann. 1994. Incidence of Klebsiella planticola
among clinical Klebsiella isolates. Med. Microbiol. Lett. 3:9095.
Podschun, R., and U. Ullmann. 1992. Isolation of Klebsiella terrigena from
clinical specimens. Eur. J. Clin. Microbiol. Infect. Dis. 11:349352.
Podschun, R., and U. Ullmann. 1992. Klebsiella capsular type K7 in relation
to toxicity, susceptibility to phagocytosis and resistance to serum. J. Med.
Microbiol. 36:250254.
Poh, C. L., S. C. Yap, and M. Yeo. 1993. Pulsed-field gel electrophoresis for
differentiation of hospital isolates of Klebsiella pneumoniae. J. Hosp. Infect.
24:123128.
Pollack, M., R. E. Niemann, J. A. Reinhardt, P. Charache, M. P. Jett, and
P. H. Hardy, Jr. 1972. Factors influencing colonisation and antibioticresistance patterns of gram-negative bacteria in hospital patients. Lancet ii:
668671.
Porat, R., M. A. Johns, and W. R. McCabe. 1987. Selective pressures and
lipopolysaccharide subunits as determinants of resistance of clinical isolates
of gram-negative bacilli to human serum. Infect. Immun. 55:320328.
Przondo-Hessek, A., and G. Pulverer. 1983. Hemagglutinins of Klebsiella
pneumoniae and Klebsiella oxytoca. Zentbl. Bakteriol. Mikrobiol. Hyg. Ser.
A 255:472478.
Przondo-Hessek, A. 1966. Bacteriophages of Klebsiella bacilli. Isolation
properties and use in typing. Arch. Immunol. Ther. Exp. 14:413435.
Ramm, L. E., M. B. Whitlow, and M. M. Mayer. 1983. Size distribution and
stability of the trans-membrane channels formed by complement complex
C5b-9. Mol. Immunol. 20:155160.
Ransjo
, U., Z. Good, K. Jalakas, I. Ku
hn, I. Siggelkow, B. berg, and E.
Anjou. 1992. An outbreak of Klebsiella oxytoca septicemias associated with
the use of invasive blood pressure monitoring equipment. Acta Anaesthesiol. Scand. 36:289291.
Reinhardt, H. H., N. Obedeanu, and J. D. Sobel. 1990. Quantitation of
Tamm-Horsfall protein binding to uropathogenic Escherichia coli and lectins. J. Infect. Dis. 162:13351340.
Reish, O., S. Ashkenazi, N. Naor, Z. Samra, and P. Merlob. 1993. An
outbreak of multiresistant Klebsiella in a neonatal intensive care unit. J.
Hosp. Infect. 25:287291.
Reissbrodt, R., and W. Rabsch. 1988. Further differentiation of Enterobacteriaceae by means of siderophore-pattern analysis. Zentbl. Bakteriol. Mikrobiol. Hyg. Ser. A 268:306317.
Rennie, R. P., and I. B. R. Duncan. 1974. Combined biochemical and
serological typing of clinical isolates of Klebsiella. Appl. Microbiol. 28:534
539.
Riser, E., and P. Noone. 1981. Klebsiella capsular type versus site of isolation. J. Clin. Pathol. 34:552555.
Roantree, R. J., and L. A. Rantz. 1960. A study of the relationship of the
normal bactericidal activity of human serum to bacterial infection. J. Clin.
Invest. 39:7281.
Rodriguez-Ortega, M., I. Ofek, and N. Sharon. 1987. Membrane glycoproteins of human polymorphonuclear leucocytes that act as receptors for
mannose-specific Escherichia coli. Infect. Immun. 55:968973.
Rose, H. D., and J. Schreier. 1968. The effect of hospitalization and antibiotic therapy on the gram-negative fecal flora. Am. J. Med. Sci. 255:228
236.
Rosebury, T. 1962. Microorganisms indigenous to man. McGraw Hill Book
Co., New York, N.Y.
Rosenthal, S., and I. B. Tager. 1975. Prevalence of gram-negative rods in
the normal pharyngeal flora. Ann. Intern. Med. 83:355357.
Rubin, S. J. 1985. Klebsiella marker systems. Infect. Control 6:5963.
Sakazaki, R., K. Tamura, Y. Kosako, and E. Yoshizaki. 1989. Klebsiella
ornithinolytica sp. nov., formerly known as ornithine-positive Klebsiella oxytoca. Curr. Microbiol. 18:201206.
Schaberg, D. R., D. H. Culver, and R. P. Gaynes. 1991. Major trends in the
microbial etiology of nosocomial infection. Am. J. Med. 91:72S75S.
Schaechter, M., G. Medoff, and B. I. Eisenstein. 1993. Mechanisms of
microbial disease, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.
Schiappa, D. A., M. K. Hayden, M. G. Matushek, F. N. Hashemi, J. Sullivan, K. Y. Smith, D. Miyashiro, J. P. Quinn, R. A. Weinstein, and G. M.
Trenholme. 1996. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J. Infect. Dis. 174:529536.
Seidler, R. J., M. D. Knittel, and C. Brown. 1975. Potential pathogens in the
environment: cultural reactions and nucleic acid studies on Klebsiella pneumoniae from clinical and environmental sources. Appl. Microbiol. 29:819
825.
Selden, R., S. Lee, W. L. Wang, J. V. Bennett, and T. C. Eickhoff. 1971.
Nosocomial Klebsiella infections: intestinal colonization as a reservoir. Ann.
Intern. Med. 74:657664.

CLIN. MICROBIOL. REV.

216. Sharon, N., and I. Ofek. 1986. Mannose specific bacterial surface lectins, p.
5581. In D. Mirelman (ed.), Microbial lectins and agglutinins. John Wiley
& Sons, Inc., New York, N.Y.
217. Simoons-Smit, A. M., A. M. J. J. Verweij-van Vught, I. Y. R. Kanis, and
D. M. MacLaren. 1985. Biochemical and serological investigations on clinical isolates of klebsiella. J. Hyg. Camb. 95:265276.
218. Simoons-Smit, A. M., A. M. J. J. Verweij-van Vught, I. Y. R. Kanis, and
D. M. MacLaren. 1985. Chemiluminescence of human leucocytes stimulated by clinical isolates of Klebsiella. J. Med. Microbiol. 19:333338.
219. Simoons-Smit, A. M., A. M. J. J. Verweij-van Vught, and D. M. MacLaren.
1986. The role of K antigens as virulence factors in Klebsiella. J. Med.
Microbiol. 21:133137.
220. Simoons-Smit, A. M., A. M. J. J. Verweij-van Vught, and D. M. MacLaren.
1984. Virulence of Klebsiella strains in experimentally induced skin lesions
in the mouse. J. Med. Microbiol. 17:6777.
221. Sirot, D. 1995. Extended-spectrum plasmid-mediated beta-lactamases. J.
Antimicrob. Chemother. 36:1934.
222. Slopek, S. 1978. Phage typing of Klebsiella. Methods Microbiol. 11:193222.
223. Slopek, S., A. Przondo-Hessek, H. Milch, and S. Deak. 1967. A working
scheme for bacteriophage typing of Klebsiella bacilli. Arch. Immunol. Ther.
Exp. 15:589599.
224. Smith, J. M. B., and S. T. Chambers. 1995. Klebsiella oxytoca revealing
decreased susceptibility to extended spectrum beta-lactams. J. Antimicrob.
Chemother. 36:265267.
225. Smith, R. F., S. L. Dayton, D. D. Chipps, and D. Blasi. 1973. Intestinal
carriage of Klebsiella and Pseudomonas in burned children and their comparative role in nosocomial infection. Health Lab. Sci. 10:173179.
226. Spencer, R. C. 1996. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur. J. Clin. Microbiol. Infect.
Dis. 15:281285.
227. Stamm, W. E., R. A. Weinstein, and R. E. Dixon. 1981. Comparison of
endemic and epidemic nosocomial infections, p. 913. In R. E. Dixon (ed.),
Nosocomial infections. Yorke Medical Books, Atlanta, Ga.
228. Stenzel, W., H. Bu
rger, and W. Mannheim. 1972. Zur Systematik und
Differentialdiagnostik der Klebsiella-Gruppe mit besonderer Beru
cksichtigung der sogenannten Oxytocum-Typen. Zentbl. Bakteriol. Mikrobiol. Hyg.
Ser. A 219:193203.
229. Straus, D. C. 1987. Production of an extracellular toxic complex by various
strains of Klebsiella pneumoniae. Infect. Immun. 55:4448.
230. Suerbaum, S., S. Friedrich, H. Leying, and W. Opferkuch. 1994. Expression
of capsular polysaccharide determines serum resistance in Escherichia coli
K 92. Zentbl. Bakteriol. 281:146157.
231. Tarkkanen, A.-M., B. Allen, B. Westerlund, H. Holthofer, P. Kuusela, L.
Risteli, S. Clegg, and T. K. Korhonen. 1990. Type V collagen as target for
type-3 fimbriae, enterobacterial adherence organelles. Mol. Microbiol. 4:
13531361.
232. Tarkkanen, A. M., R. Virkola, S. Clegg, and T. K. Korhonen. 1997. Binding
of the type 3 fimbriae of Klebsiella pneumoniae to human endothelial and
urinary bladder cells. Infect. Immun. 65:15461549.
233. Taylor, P. W. 1983. Bactericidal and bacteriolytic activity of serum against
gram-negative bacteria. Microbiol. Rev. 47:4683.
234. Taylor, P. W., and H.-P. Kroll. 1985. Effect of lethal doses of complement
on the functional integrity of target enterobacteria. Curr. Top. Microbiol.
Immunol. 121:135158.
235. Tessin, I., B. Trollfors, and K. Thiringer. 1990. Incidence and etiology of
neonatal septicaemia and meningitis in Western Sweden 19751986. Acta
Paediatr. Scand. 79:10231030.
236. Thom, B. T. 1970. Klebsiella in faeces. Lancet ii:1033.
237. Toma
s, J. M., V. J. Bened, B. Ciurana, and J. Jofre. 1986. Role of capsule
and O antigen in resistance of Klebsiella pneumoniae to serum bactericidal
activity. Infect. Immun. 54:8589.
238. Toma
s, J. M., S. Camprubi, and P. Williams. 1988. Surface exposure of the
O-antigen in Klebsiella pneumoniae O1:K1 serotype strains. Microb. Pathog.
5:141147.
239. Tullus, K., B. Berglund, B. Fryklund, I. Ku
hn, and L. G. Burman. 1988.
Epidemiology of fecal strains of the family Enterobacteriaceae in 22 neonatal wards and influence of antibiotic policy. J. Clin. Microbiol. 26:1166
1170.
240. Tullus, K., B. Olsson-Liljequist, G. Lundstrom, and L. G. Burman. 1991.
Antibiotic susceptibility of 629 bacterial blood and CSF isolates from swedish infants and the therapeutic implications. Acta Paediatr. Scand. 80:205
212.
241. Ullmann, U. 1983. The distribution of Klebsiella pneumoniae serotypes from
different sources and their sensitivity to cephalosporins. Infection 11:S28
S31.
242. Ullmann, U. 1986. Pattern of microbial isolates in hospitalized patients.
Zentbl. Bakteriol. Mikrobiol. Hyg. Ser. B 183:103113.
243. Urban, C., and J. J. Rahal. 1997. Klebsiella and extended spectrum blactamases. Int. J. Antimicrob. Agents 8:3743.
244. Venegas, M. F., E. L. Navas, R. A. Gaffney, J. L. Duncan, B. E. Anderson,
and A. J. Schaeffer. 1995. Binding of type 1-piliated Escherichia coli to
vaginal mucus. Infect. Immun. 63:416422.

VOL. 11, 1998

245. Venezia, R. A., F. J. Scarano, K. E. Preston, L. M. Steele, T. P. Root, R.
Limberger, W. Archinal, and M. A. Kacica. 1995. Molecular epidemiology
of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin. Infect. Dis. 21:
915923.
246. Vermeulen, C., A. Cross, W. R. Byrne, and W. Zollinger. 1988. Quantitative
relationship between capsular content and killing of K1-encapsulated Escherichia coli. Infect. Immun. 56:27232730.
247. Vesikari, T., E. Isolauri, N. Tuppurainen, M. Renlund, M. Koivisto, M.
Janas, R. S. Ikonen, P. Kero, K. Heinonen, R. Nyman, and M. Kunnas.
1989. Neonatal septicaemia in Finland 198185. Acta Paediatr. Scand. 78:
4450.
248. Virkola, R., B. Westerlund, H. Holthofer, J. Parkkinen, M. Kekoma
ki, and
T. K. Korhonen. 1988. Binding characteristics of Escherichia coli adhesins in
human urinary bladder. Infect. Immun. 56:26152622.
249. Vosti, K. L., and E. Randall. 1970. Sensitivity of serologically classified
strains of Escherichia coli of human origin to the serum bactericidal system.
Am. J. Med. Sci. 259:114119.
250. Walia, S., T. Madhavan, P. Reuman, R. Tewari, and D. Duckworth. 1988.
Plasmid profiles and klebocin types in epidemiologic studies of infections by
Klebsiella pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 7:279284.
251. Williams, P., H. Chart, E. Griffiths, and P. Stevenson. 1987. Expression of
high affinity iron uptake systems by clinical isolates of Klebsiella. FEMS
Microbiol. Lett. 44:407412.
252. Williams, P., P. A. Lambert, M. R. W. Brown, and R. J. Jones. 1983. The
role of the O and K antigens in determining the resistance of Klebsiella
aerogenes to serum killing and phagocytosis. J. Gen. Microbiol. 129:2181
2191.

KLEBSIELLA SPECIES AS NOSOCOMIAL PATHOGENS

603

253. Williams, P., M. A. Smith, P. Stevenson, E. Griffiths, and J. M. T. Tomas.

1989. Novel aerobactin receptor in Klebsiella pneumoniae. J. Gen. Microbiol. 135:31733181.
254. Williams, P., and J. M. Tomas. 1990. The pathogenicity of Klebsiella pneumoniae. Rev. Med. Microbiol. 1:196204.
255. Wooldridge, K. G., and P. H. Williams. 1993. Iron uptake mechanisms of
pathogenic bacteria. FEMS Microbiol. Rev. 12:325348.
256. Wu
rker, M., J. Beuth, H. L. Ko, A. Przondo-Modarska, and G. Pulverer.
1990. Type of fimbriation determines adherence of Klebsiella bacteria to
human epithelial cells. Zentbl. Bakteriol. 274:239245.
257. Yancey, R. J., S. A. L. Breeding, and C. E. Lankford. 1979. Enterochelin
(enterobactin): virulence factor for Salmonella typhimurium. Infect. Immun.
24:174180.
258. Yinnon, A. M., A. Butnaru, D. Raveh, Z. Jerassy, and B. Rudensky. 1996.
Klebsiella bacteremia: community versus nosocomial infection. Monthly J.
Assoc. Physicians 89:933941.
259. Yokochi, T., Y. Inoue, Y. Kato, T. Sugiyama, G. Z. Jiang, M. Kawai, M.
Fukada, and K. Takahashi. 1995. Strong adjuvant action of Klebsiella O3
lipopolysaccharide and its inhibition of systemic anaphylaxis. FEMS Immunol. Med. Microbiol. 10:181184.
260. Yokochi, T., I. Nakashima, and N. Kato. 1977. Effect of capsular polysaccharide of Klebsiella pneumoniae on the differentiation and functional capacity of macrophages cultured in vitro. Microbiol. Immunol. 21:601610.
261. Yokochi, T., I. Nakashima, and N. Kato. 1979. Further studies on generation of macrophages in in vitro cultures of mouse spleen cells and its
inhibition by the capsular polysaccharide of Klebsiella pneumoniae. Microbiol. Immunol. 23:487499.